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ABSTRACT 
To be able to target cells of interest is one of the key aims in medicine today, because 
it could minimize side effects of drugs. This is of special importance in cancer 
therapies, were the treatment has serious side-effects on the patients healthy cells. 
Nanomedicine seeks to overcome this limitation by utilizing nanoparticles as drug 
carriers, as nanoparticles have shown considerable potential as targeted drug delivery 
systems and could thus be used in cancer treatment. The key is to figure out a novel 
way of targeting cells of interest; what are the differences in these cells that could be 
used as a Trojan horse for delivering the drug to the target tissue. The trick, however 
is to find what drug would benefit from being loaded to a nanoparticle carrier system. 
What drug incorporation method is plausible, what pore size can harbor that specific 
drug, what particle size would be optimal to be internalized without unspecific 
uptake? What kind of surface functionalization would yield the highest uptake in the 
cancer cell of interest and what could be the potential unwanted off-target effects? 
In this thesis, we exploited the increased metabolism of cancer cells and high 
replication rate for designing mesoporous silica nanoparticles (MSNs) for targeted 
drug delivery. The faster a cell grows and divides, the higher the metabolism rate and 
DNA synthesis is, and thus, increased uptake of both glucose and folate molecules 
occurs. We used these cancer specific traits aiming for actively targeted drug delivery 
by either functionalizing the particle with sugar moieties, folic acid or its antagonist 
methotrexate. Subsequently, by loading the particles with molecules that intervene 
with processes that are more pronounced in cancer cells than healthy cells, it was 
possible to increase drug selectivity and efficacy even further.  
In the first study, we loaded the particles with celastrol, which is an active molecule 
used in traditional Chinese medicine that has the ability to induce cell death in cancer 
cells that have a high rate of mitosis through destabilizing the mitotic spindle. In the 
second study, we utilized celastrol’s ability in lower dosages to induce the heat shock 
response which could be beneficial in cells that suffer from protein aggregates, as 
increase in heat shock proteins can help remodel these aggregates back to their native 
form. This kind of targeted heat shock response could be beneficial for patients 
suffering from neurodegenerative diseases such as Alzheimer’s and Parkinson’s. In 
order to identify the cells that have induced the heat shock response, we created a 
tailor-made automated image analysis workflow based on the freely available 
BioImageXD software that can be used for numerous biological scenarios.  
In the third and last study, we conjugated the nanoparticle with methotrexate (MTX) 
that acts as a folic acid antagonist and have been used in decades for chemotherapy; 
in this manner, we can create a targeting ligand that has an efficacy by itself. The 
benefit of using MTX as targeting ligand is that it opens the possibility to load the 
nanoparticle with a second active molecule that would further increase the efficacy of 
the treatment. This multidrug-loaded nanoparticle could be used for metastatic cancer 
therapy when conventional cancer treatments have a severe negative effect on the 
patient. The nanoparticle would seek the metastatic cell with the targeting ligand 
MTX, and then together with the second active molecule, in this case fingolimod 
(FTY720), induce apoptosis and stop the invading cancerous cell.   
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SAMMANFATTNING 
Målstyrd läkemedelsbehandling och därmed minimeringen av biverkningar av 
läkemedel är viktiga forskningsområden inom medicin för tillfället. Minimeringen av 
biverkningarna är av särskild betydelse I samband med cancerterapier. Eftersom 
behandlingarna oftast har allvarliga biverkningar för patienten finns ett stort behov av 
nya och mer specifika behandlingsformer inom cancervård. Ett potentiellt sätt att 
uppnå målstyrd läkemedelsbehandling inom cancervård är att utnyttja nanopartiklar 
som läkemedelsbärare. Målsättningen är att läkemedlet upptas specifikt av 
cancercellerna och därmed minskar biverkningarna hos patienten. Nyckeln till att 
uppnå målstyrd läkemedelsbehandling är att hitta ett sätt att leverera läkemedlet 
specifikt åt cancercellerna med betydligt mindre upptagning hos de friska cellerna i 
resten av kroppen. Den avgörande frågan är, vilka unika egenskaper hos 
cancercellerna kan utnyttjas för att leverera läkemedlet specifikt till målvävnaderna. 
När det gäller nanopartiklar för målstyrd läkemedelsbehandling måste man även 
utreda vilka läkemedel som kunde dra nytta av att fyllas med eller konjugeras till en 
partikel, vilka läkemedelsintegreringsmetoder är möjliga samt vilken 
funktionalisering som ger upphov till största möjliga upptagning hos cancercellerna. 
Även partikel- och porstorleken har betydelse för upptagningen av läkemedlet. 
Dessutom är det viktigt att kartlägga de potentiella biverkningarna för att kunna föra 
vidare utvecklingen av nanopartiklar för målstyrd läkemedelsbehandling. 
Denna avhandling innehåller tre akademiska studier där cancercellers avvikande 
egenskaper utnyttjas för att uppnå målstyrd läkemedelsbehandling. I den första 
studien utnyttjades cancercellers höga metabolism och ökade behov av socker. Genom 
att konjugera glukos till nanopartikeln levererades läkemedlet specifikt till de socker-
hungriga cancercellerna. Nanopartikeln fylldes med läkemedlet celastrol som har 
förmågan att destabilisera mikrotubuli-nätverket i cancercellerna, vilket bidrar till att 
cancercellerna dör.  
I den andra studien utnyttjades cancercellers tendens att uttrycka folsyra-receptorer på 
cellmembranet för att specifikt leverera små mängder celastrol till målcellerna för att 
aktivera den cellulära stressresponsen. Detta i sin tur ökar på mängden molekylära 
chaperoner som skyddar celler mot proteinaggregeringar genom att återställa 
proteinernas ursprungliga konfiguration. Proteinansamlingar är associerade med olika 
neurodegenerativa sjukdomar och därför kunde denna typ av behandling vara till nytta 
för patienter som lider av t.ex. Alzheimer och Parkinsons sjukdom. För att sedan 
identifiera vilka celler som aktiverat sin stressrespons skapade vi en skräddarsydd 
bildanalysmetod. Metoden är baserad på den fritt tillgängliga BioImageXD-
programvaran och kunde användas för diverse olika biologiska scenarier. I den tredje 
och sista studien undersökte vi ifall den traditionella cytostatikan metotrexat (MTX), 
som är en folysra-antagonist, även kunde användas som målsökande ligand. Detta i 
sin tur möjliggör att partiklens inre kunde fyllas med ytterligarare ett läkemedel, i 
detta fall valdes molekylen fingolimod (FTY720) som tillsammans med cytostatikan 
skulle hämma cancercellers migration och inducera apoptos. Denna kombinatoriska 
nanopartikel skulle inte bara vara mer effektiv mot maligna tumörer än traditionell 
kemoterapi, utan patienten skulle också gynnas av betydligt lindrigare biverkningar. 
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1. INTRODUCTION 
Multicellular organisms that are built from trillions of cells need a delicate system to 
maintain cellular homeostasis, if this equilibrium is disrupted diseases are likely to 
occur. Manifested for example as accumulation of cells, due to lack of cell death is a 
prime cause for diseases such as cancer and uncontrolled clonal expansion of immune 
cells. On the other hand, excessive cell removal can lead to tissue loss that may 
develop to neurodegenerative diseases for example Huntington’s and Alzheimer’s 
disease or to a degenerative disorder of organs such as liver cirrhosis and muscular 
dystrophies.  
The knowledge from death signaling and cell survival can be used to create new 
innovative and effective treatments towards diseases that are caused by disruption in 
the cell homeostasis. In the case of cancer, where the cells have desensitized 
themselves from apoptotic stimuli and hijacked the cell survival machinery, it is 
crucial to know what specific part of the cell homeostasis pathway needs to be 
targeted, as this would maximize the efficacy of the treatment and minimize the side 
effects of the drug. However, many drug compounds have either poor solubility or 
low permeability rendering them to problematic drug candidates with limited 
therapeutic efficacy. Nanomedicine seeks to overcome these limitations by utilizing 
material in the nanoscale as drug carrier that possesses the ability to encapsulate the 
drug and thereby preventing premature release in healthy tissues. Materials in the 
nanoscale can acquire unique properties for example increased chemical reactivity, 
electrical conductivity, magnetic properties and most importantly the surface area 
increases significantly providing a closer contact with the biological surrounding 
facilitating the reactions with the living material. Combining these acquired properties 
with the possibility to produce high loading degree man-made nanocarriers with tailor 
made ligand functionalization have opened a new dimension in drug development and 
diagnostics. However, there is no “holy grail” neither a “magic bullet” that would cure 
all diseases as different conditions have different genetic and phenotypic traits. For 
example, one effective targeting ligand towards a specific type of cancer would most 
likely not be effective towards a neurodegenerative disease. Furthermore, the nano-
carrier itself needs to be biocompatible and biodegradable minimizing the adverse 
effect on the patents making the development of the drug carrier even more difficult. 
Not to mention the issues of upscaling the manufacturing procedure from an academic 
laboratory-developed nanoparticle to a cost effective largescale manufacturing plant. 
As well as the monetary problem of developing and patenting these drug innovations, 
as the accumulative costs of research and development goes up to several millions of 
dollars, money that are not necessary included in traditional research grant funding.  
In spite of the many hurdles the development of nanomaterials are facing; there are 
some Food and Drug Administration (FDA) approved nanomedicine in the market 
showing that the efforts are not futile in the pursuit of targeted medicine. Especially 
amorphous silica nanoparticles have shown great potential to be used in biomedical 
applications due to high adsorption capacity, almost endless functionalization 
possibilities, biocompatible and simply because silica based materials are “generally 
recognized as safe” (GRAS) by the FDA.  
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2. REVIEW OF THE LITERATURE 
2.1 Characteristics of cancer cells 
The word 'cancer' originates from an observation over 2300 years ago by Hippocrates 
where the veins from breast tumors looked like the limbs of a crab, and from this 
observation the term karkinoma in Greek and later on the word cancer in Latin came 
from. Cancer is not one disease and should not be consider as such, rather realize that 
cancer is a group of over 100 diseases that develop over time from disruption in the 
cellular homeostasis (Cooper 2000, Broxmeyer 2004). Cancer can develop anywhere 
in the body and even though the basic processes of cancer development is the same, 
each cancer has its own unique set of features that depends on what cell type and 
genetic background it originates from (Hanahan & Weinberg 2000). The 
transformation towards a cancerous cell begins when a cell acquire an genetic or 
epigenetic change that lets the cell break free from the normal cell division and starts 
to proliferate abnormally (Figure 1). A genetic change can happen through an internal 
replication error during mitosis predisposed by specific hereditary traits or by 
spontaneous mutation caused by environmental factors e.g. radiation, ultraviolet (UV) 
light, tobacco smoke, carcinogens in diet or infectious disease (Anand et al. 2008). 
These mutations could either be a gain-of-function in a proto-oncogene functioning 
as a growth-stimulating signal such as H-Ras mutation or as a loss-of-function 
mutation in a tumor suppressor gene such as retinoblastoma (Rb) that normally 
functions as a brake in proliferation and activator of pro-apoptotic signaling pathways 
(Lee et al. 2010a, Ozaki & Nakagawara 2011, Hilgendorf et al. 2013). 
 
 
Figure 1. Schematic representation of tumor development. A malignant tumor develops over 
time, where the first mutation gives the cell growth advantage. The next stage starts by decreasing 
sensitivity to anti-growth signals by mutation in the Rb gene, then the transforming cell needs 
insulin like growth factors in order to grow and evade apoptosis. For the cancer to continue to grown 
and divide, limitless replicative potential needs to be achieved through activating the telomerase 
function for repairing shortening DNA strands. The excessive tumor growth results in deprivation 
of oxygen, circumvented by producing vascular endothelial growth factor for stimulating new blood 
vessels to grow towards the tumor. The last steps in cancer progression where the epithelial cells 
obtain a more mesenchymal phenotype and starts breaking down the surrounding tissue and invades 
the circulation and metastasize new locations in the body (adapted from Cooper 2000, Hanahan & 
Weinberg 2000). 
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In order for the transforming cell to continue to grow and eventually become a 
malignant tumor, several function needs to be acquired. For example, the cells ability 
for self-destruct (apoptosis) must be impaired often through p53 mutation, self-
sufficiency in growth signals by mutated insulin-like growth factor 1 receptor (IGF-
1). Furthermore, upregulated metabolism by constitutively active c-Myc, limitless 
replicative potential through upregulated telomerase expression, increased 
vascularization followed by tissue invasion and metastasis affecting organ functions 
that can be lethal (Hanahan & Weinberg 2000, Miller et al. 2012, Jafri et al. 2016). In 
more details, the excessive growth of the primary tumor results in deprivation of 
oxygen and nutrients, and to overcome this obstacle the cancer cells have to start 
producing vascular endothelial growth factor (VEGF) for stimulating new blood 
vessels to grow inside the tumor a process called angiogenesis (Carmeliet 2005, Goel 
& Mercurio 2013). In the next step in tumor progression, the cancer cells need to 
obtain migratory and invasive properties in order to metastasize other tissues. A 
developmental process called epithelial–mesenchymal transition (EMT) where the 
sheet-like epithelial cells that expressed E-cadherins starts taking more of an 
mesenchymal phenotype increasing the expression of N-cadherins, allowing the 
cancer cell to acquire mobility and coming loose from their neighboring cells (Kalluri 
& Weinberg 2009). This local invasion combined with the secretion of matrix 
metalloproteinases (MMPs) that breaks down the extracellular matrix (ECM) allows 
the cancer cell to enter the vasculature (Gialeli et al. 2010). After entry to the blood 
circulation, the cancer cells must evade the immune system, infiltrate tissues, and 
colonize new organs for successful metastasis and the formation of a secondary tumor 
(Chambers et al. 2002, Nguyen et al. 2009). All of these separate steps in cancer 
progression could potentially be utilized for cancer therapies if the details of what 
cellular signaling pathway is deregulated.  
2.2 Conventional cancer therapeutics 
Historically treatment of solid tumors has mainly relied on surgery, radiation and 
chemotherapy (Sudhakar 2009, Arruebo et al. 2011). Already over 2000 years ago 
surgeries have been used to remove skin abnormalities in similar manners as today, 
however recurrence of the tumor is not unusual when relying solely on surgery 
(Sudhakar 2009). The discovery of X-rays and radiation in the late 19th century by 
Rontgen and Becquerel paved the way for the development of radiotherapy and the 
first cured cancer case was in 1889. The clinical use of chemotherapy started in the 
1930s based on the observations during the first and second world war that soldier 
exposed to mustard gas had decreased levels of leukocytes (Arruebo et al. 2011). The 
technological and clinical advances in the 1960s made it possible to develop a more 
sophisticated cancer treatment with instruments such as “Clinac 6” that used focused 
X-rays combined with chemotherapy for achieving higher success rates in curing 
cancer (Sudhakar 2009, Arruebo et al. 2011). Most of the traditional chemotherapy 
still in use today attacks the abrupted cellular homeostasis of cancer cells manifested 
by their increased proliferation and replication rate (Malhotra & Perry 2003). 
Normally such high replication rates are only seen in developmental stages and not in 
an adult body as most of the tissues and organs are already developed (Kermi et al. 
2017). Therefore, using antimitotic drugs including taxanes (e.g. Taxol®) and vinca 
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alkaloids (e.g. Velban®) that intervenes with processes that are involved with cell 
division it is possible to eliminate tumors without lethal consequences to the adult 
post-mitotic cells (Seligmann & Twelves 2013). Other chemotherapies relies on 
inducing irreparable DNA damage for example alkylating agents and platinum drugs; 
as many cancers have impaired cell cycle checkpoints these cells enter mitosis 
regardless of the chromosomal damage followed by mitotic catastrophe (Castedo 
2004, Nakanishi et al. 2006). Methotrexate (MTX) and 5-fluorouracil (5-FU) are 
antagonists that mimic building blocks essential for DNA synthesis thus preventing 
cell division in proliferating tumors (Goodsell 1999). Anthracycline are a class of 
antitumor antibiotics derived from the bacterium Streptomyces peucetius var. caesius 
from which doxorubicin and daunorubicin are the most common drugs discovered in 
the 1970s (Fujiwara et al. 1985, Thorn et al. 2011). The antitumor properties of these 
drugs involves inhibition of the enzyme topoisomerase II responsible of separating 
DNA strands during replication leading towards entangled chromosomes resulting in 
cell cycle arrest followed by apoptosis (Thorn et al. 2011). Other natural derived 
compounds frequently used in chemotherapy are bleomycin, enediynes, and 
mitomycin which cytotoxic mechanism involves the oxidative cleavage of DNA and 
RNA strands (Galm et al. 2005). Each treatment has their benefits and limitations and 
therefore cancer therapies relies often on combinatory treatment of surgery, 
radiotherapy and chemotherapy.  
2.3 Challenges in traditional chemotherapy 
Conventional chemotherapy have diverse side effects ranging from hair loss, weight 
loss, anemia and nausea to organ problems as the drug is systematically administered 
where it affects the whole body (O'Brien et al. 2006, Farokhzad & Langer 2009, 
Ramirez et al. 2009). The efficacy of drugs traditionally used in chemotherapy affects 
either cell proliferation or induces DNA damage that also damage healthy tissues 
especially cells that are under constant renewal such as hair follicles, epithelial cells 
of the intestine blood cells in the bone marrow and egg cells affecting fertility (Allan 
& Travis 2005, Blumenfeld 2012, Palumbo et al. 2013). Alkylating agents and 
platinum drugs which efficacy relies on inducing DNA damage in fast dividing cancer 
cells has the risk of mutating healthy cells or inducing irreparable chromosomal 
damage in normal tissues giving potential off-targeting effects (Allan & Travis 2005). 
In addition, cancer cells exhibit genomic instability as the mutation rate is 
significantly increased, which under selective pressure could result in resistance to the 
therapy administered (Gottesman et al. 2002). The molecular mechanisms behind 
cancer drug resistance include by not limited to; inhibition of drug import, increased 
drug efflux, increased ability to metabolize and detoxify the drug (Housman et al. 
2014). For example, overexpression of the ATP-binding cassette (ABC) transporters 
in multi-resistant cancers enables transporting of drug molecules away from the 
intracellular compartment thus lowering the drug concentrations in these cancers to 
sub-lethal evading the effect of chemotherapy (Izquierdo et al. 1996). Combined with 
altered surrounding stromal tissue and dormant cancer stems cells that strengthen and 
rejuvenates the tumor, rendering the disease of cancer to a difficult one to combat 
(Papaccio et al. 2017, Landry et al. 2018). Therefore, modern chemotherapy often 
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contains a cocktail of many drugs that unfortunately also increases the risk of 
unwanted side effects for the patient (O'Brien et al. 2006, Hu et al. 2016).  
Furthermore, the drug efficacy depends on the availability of the active substance 
inside the tumor cell influenced by the drug concentration in the blood plasma that 
relates to drug solubility in aqueous solution, as well as to the drug permeability 
allowing the molecule to pass biological membranes such as the cell membrane of the 
tumor. These two parameters, solubility and permeability, are evaluated in oral drug 
development using the standardized Biopharmaceutical Classification System (BCS; 
Figure 2; Benet 2012). A drug is considered highly soluble when the highest dose 
strength of an immediate release product is soluble in 250 ml or less of aqueous media 
where the pH ranges from 1 to 7.5. The drug permeability correlates directly to the 
lipophilicity of the compound, which can be calculated based on measurements of 
drug efflux across human intestinal membrane. A drug substance is considered highly 
permeable when over 90% of the compound is absorbed over the intestinal membrane 
and there is no evidence showing instability of the compound in the gastrointestinal 
tract (Amidon et al. 1995, Savjani et al. 2012). However, current trends in drug 
development are heading towards molecules that are more complex with greater 
lipophilicity and higher molecular weight resulting in low aqueous solubility. Issues 
related with poor water solubility such as suboptimal delivery of the drug and low 
bioavailability are some of the major reasons of failures in modern drug development. 
As around 90% of current drugs under development and 40% of approved drugs in 
the market are poorly water-soluble (Kalepua et al. 2015). 
 
Figure 2. Biopharmaceutical Classification System (BCS; adapted from Benet 2012).  
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2.4 Towards targeted cancer therapies  
Cancer therapeutics is headed towards personalized drug therapy and diagnostics 
where tailor made drug compounds are assigned to each individual patient for 
minimizing side effects and maximizing efficacy (Hanahan & Weinberg 2000). The 
first approved targeted cancer drug was tamoxifen in the 1970s, which effects is based 
on binding to the estrogen receptor (ER) blocking estrogens ability of stimulating ER-
positive breast cancer cell growth (Yan et al. 2011). During the past decades, the 
discovery of oncogenes and tumor suppressor genes combined with the completion of 
the human genome has given insight in the mechanism of cancer development. There 
are more than 100 oncogenes and tumor suppressor genes known today that after 
mutation transforms a normal cell towards a cancerous one. Therefore, inhibiting the 
function of such mutated oncoproteins or tumor suppressor proteins by small-
molecules or monoclonal antibodies for targeted therapy it would be possible stop fast 
dividing cancer cells without inducing undesirable side effects (Yan et al. 2011, Sun 
et al. 2017b). There are already some targeted therapies that have been approved by 
the Food and Drug Administration (FDA) for treatment of patients with different 
forms of cancers (Table 1). For example, small molecules e.g. pazopanib that inhibit 
the angiogenesis at the tumor site by targeting the vascular endothelial growth factor 
(VEGF) or by inhibiting tumor growth by drugs such as gefitinib that targets 
epidermal growth factor receptor (EGFR) or by regorafenib that binds to fibroblast 
growth factor receptor 2 (FGFR2; Table 1; Yan et al. 2011). The research and 
development (R&D) of monoclonal antibodies started around 1975 and the first 
market-approved antibody to be used for reducing the risk of kidney transplant 
rejection was Orthoclone OKT3 in 1986. Monoclonal antibodies to be used in cancer 
therapeutics include trastuzumab (Herceptin) that binds to the extracellular domain of 
the human epidermal growth factor receptor 2 (HER2) thus blocking its function 
slowing down the growth of malignant HER2 positive breast cancer cells (Hortobagyi 
2001, Sun et al. 2017b). The drug-linked monocolonal antibody gemtuzumab 
functions as a cancer immunotherapy binding to CD-33 receptor expressed on 
myeloid leukemia cells while releasing the cargo calicheamicin (Padma 2015). There 
are also some attempts on stimulating the immune system to destroy the cancerous 
cell by vaccination; currently there is only one FDA approved vaccine named 
Sipuleucel-T manufactured by Dendreon (Butterfield 2015). Other targeted therapies 
includes prodrugs such as imatinib (Gleevec®) that are inactive derivate of the active 
drug molecules that have to undergo an enzymatic transformation to regenerate to its 
active form. Many enzymes are upregulated in cancer cells that can be targeted by 
prodrugs that are incorporated with appropriate substrates so that the upregulated 
enzyme(s) such as lysosomal proteases, ECM proteases and/or MMPs cleaves the 
prodrug at the tumor site to its active form and unleashes its cytotoxic effect (Giang 
et al. 2014, Padma 2015). Additionally, gene therapy might succeed in curing cancers 
by replacing the mutated oncogene such as p53 with the normal wild-type, attempts 
in gene therapy for head and neck cancer patents have shown to be beneficial (Bali et 
al. 2013). In the future, a tailored drug-cocktail for each mutated oncogene or tumor 
suppressor driven cancer might be the most efficient therapy as it is highly unlikely 
that one drug would cure them all due to the ever-changing cancer phenotype. 
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Table 1. FDA approved targeted cancer therapies 2003-2013 (adapted from Yan et al. 2011, 
Padma 2015, Sun et al. 2017b). 
Compound Company /Year Type Target(s) Indication* 
Ado-
trastuzumab 
emtansine 
Genentech /2013 Antibody HER2 Breast cancer 
Regorafenib Bayer /2012 Drug PDGFR, FGFR Colorectal cancer 
/Stomach cancer 
Denosumab Amgen /2010 Antibody TNFSF11 Bone metastases 
Everolimus Novartis /2009 Drug mTOR Renal cell carcinoma 
Ofatumumab Genmab /2009 Antibody CD-20 Chronic lymphocytic 
leukemia 
Pazopanib GSK /2009 Drug VGFR-1, -2,  
-3, c-kit, 
PDGFR 
Renal cell carcinoma 
Romidepsin Gloucester /2009 Drug HDAC Cutaneous T cell 
lymphoma 
Lapatinib GSK /2007 Drug HER2/EGFR Breast cancer 
Nilotinib Novartis /2007 Small 
molecule 
BCR-ABL Chronic myelogenous 
leukemia 
Temsirolimus Wyeth /2007 Drug mTOR Renal cell carcinoma 
Dasatinib Bristol-Myers 
Squibb /2006 
Drug Src, BCR-ABL Chronic myeloid 
leukemia 
Panitumumab Amgen /2006 Antibody EGFR Colorectal carcinoma 
Sunitinib 
malate 
Pfizer /2006 Small 
molecule 
VGFRs, 
PDGFR 
Gastrointestinal 
stromal tumor 
Vorinostat Merck /2006 Drug HDAC Cutaneous T-cell 
lymphoma 
Sorafenib 
Tosylate 
Bayer /2005 Drug RAF, VEGFR-
2, -3, PDGFR-
b, c-kit 
Renal cell carcinoma 
Bevacizumab Genentech /2004 Antibody VEGF Colorectal cancer 
Cetuximab ImClone Systems 
/2004 
Antibody EGFR Colorectal cancer 
Erlotinib 
Hydrochloride 
OSI Pharms /2004 Drug EGFR Non-small cell lung 
cancer 
Bortezomib Millennium 
Pharms /2003 
Drug Proteasome Multiple myeloma 
Gefitinib AstraZeneca /2003 Drug EGFR Non-small cell lung 
cancer 
Tositumomab  Corixa 
Corporation /2003 
Antibody CD-20 Non-Hodgkin's 
lymphoma 
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2.5 Regulation of programmed cell death 
Apoptosis is the term that was first used by Kerr, Wyllie and Currie in 1972 to describe 
programmed cell death in eukaryotes for maintaining cell populations in tissues (Kerr 
et al. 1972). Eukaryotic cells have two major apoptotic pathways, the intrinsic 
pathway and the extrinsic pathway (Figure 3) The intrinsic pathway is activated by 
cellular stresses; such as radiation, oxidative stress and cytotoxic drugs leading 
towards mitochondrial membrane leakage, DNA damage and finally cell death 
(Elmore 2007, Kroemer et al. 2009). If the cell stress is non-lethal, the anti-apoptotic 
B-cell lymphoma gene 2 (Bcl-2) family proteins blocks the intrinsic apoptotic stimuli 
(Hongmei 2012). However if the trauma is irreparable, the intrinsic pro-apoptotic 
proteins Bax and Bak are activated leading to mitochondrial outer membrane 
permeabilization (MOMP) that allows the leakage of electron carrier protein called 
cytochrome c. This accumulation of cytochrome c in the cytosol promotes 
apoptosome formation and activation of initiator caspases which in turn activates 
executioner caspases that ultimately leads to apoptosis (Elmore 2007, Hongmei 2012). 
The extrinsic apoptotic pathway is mediated by death receptors (DRs) that are 
members of the tumor necrosis factor receptor superfamily (TNF; Elmore 2007). 
There are over twenty DRs and of them, eight has the ability to induce apoptosis, of 
which Fas/CD95-receptor is one of the best characterized (Aggarwal 2003). When the 
death ligand binds to the DR; a conformational change takes place in the intracellular 
region of the receptor leading to recruitment of an adaptor protein named Fas-
associtated death domain (FADD). Together creates a platform for death effector 
domain (DED)-containg proteins to bind and form death-inducing signaling complex 
(DISC). When the initiator procaspase is recruited to the DISC, the procaspase is 
cleaved to its active form and then released to the cytosol where the active caspase 
initiates the apoptotic proteolytic cascade (Aggarwal 2003 Boatright et al. 2003, 
Elmore 2007). Ultimately leading towards cell death, which is manifested by nuclear 
and cytoplasmic condensation, plasma membrane blebbing and DNA fragmentation 
(Kroemer et al. 2009, Hongmei 2012). These cell fragments are called apoptotic 
bodies and are then engulfed by professional phagocytes thereby preventing the 
inflammatory response (Nagata 2018). Necrosis is traditionally defined as 
uncontrolled cell death, where the cells have undergone an accident leading towards 
membrane swelling and cell rapture resulting to release of cellular content, which 
causes a local inflammation in the surrounding tissues (Kroemer et al. 2009). 
However, evidence are accumulating that necrosis can even occur in a more controlled 
manner, nowadays defined as necroptosis (Golstein & Kroemer 2007). There are other 
forms of cell death, such as anchorage-dependent programmed cell death called 
anoikis where the cell have lost its cell to matrix interaction or by cornification of 
keratinocytes which is necessary for the formation of the epidermis (Kroemer et al. 
2009). Drugs such as Taxol® disrupt microtubule formation during cell division 
killing the cell through mitotic catastrophe (Denisenko et al. 2016). Macrophages that 
have a bacterial infections might die through pyroptosis which is an inflammation 
reaction driven by caspase-1 (Galluzzi et al. 2012, Kroemer et al. 2009). The balance 
between different pathways of controlled or uncontrolled cell death depends on the 
nature and severity of the death stimulus and cell type. 
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Figure 3. Schematic representation of the apoptotic signaling pathway. Programmed cell death 
can be initiated by either extrinsic or intrinsic stimulus. The extrinsic apoptosis is activated by death 
ligand binding to death receptor (DR) leading to the formation of a death inducing signaling 
complex (DISC). The intracellular death domain facilitates the cleavage and activation of the 
initiator caspase-8, which in turn activates downstream executioner caspases that starts the cleavage 
of cellular compartments leading towards apoptosis. However, by receiving pro-survival signals it 
is possible for the cell to prevent the extrinsic apoptotic signaling cascade by blocking the activation 
of the initiation caspase by cellular FLICE-inhibitory proteins (c-FLIP) binding to the DISC. The 
pro-apoptotic proteins Bax and Bak together with the anti-apoptotic Bcl-2 proteins balance the 
apoptotic stimuli by regulating the integrity of the mitochondrial membrane. The intrinsic apoptotic 
signaling pathways activates by irreparable cellular damage resulted from radiation, chemicals, UV 
light or pathogens that leads to mitochondrial outer membrane permeabilization (MOMP). 
Followed by the release of cytochrome c that promotes APAF-1 oligomerisation and the formation 
of the apoptosome, which serves as a platform for caspase-9 and together strengthens the apoptotic 
cascade. The inhibitors of apoptosis proteins (IAPs) can block the activation of caspase-9 and thus 
preventing the formation of the apoptosme, however, Smac/Diablo can, after leaking out of the 
mitochondria block the IAPs so that the apoptotic pathway may still prevail. 
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2.5.1 Caspases are the executors of apoptosis 
All eukaryotic cells have the possibility of self-destruction, in other words 
programmed cells death in which cysteine-dependent aspartate proteases called 
caspases are the main executors (Kroemer et al. 2009). These caspases are synthesized 
as inactive procaspases which upon apoptotic stimuli are then dimerized in close 
proximity to each other leading to a proteolytic cleavage resulting in an active initiator 
caspase (caspase-2, -8, -9, -10), amplifying the apoptotic stimuli (Elmore 2007). 
These stimulated initiation caspases proteolytically activates in turn the downstream 
executioner caspases (caspase-3, -6, -7) that are responsible for the cleavage of 
cellular compartments leading toward apoptosis (Hongmei 2012). Caspase-1 on the 
other hand is the part of the inflammasome complex that promotes cytokine 
maturation and secretion, induced by bacterial infection (Franchi et al. 2009). The 
main objective in these sequential signaling cascades is that it function as an 
amplification from the original death stimuli (Elmore 2007). However, in order to 
maintain cellular homeostasis it is crucial that the apoptotic stimuli is kept under strict 
control otherwise the cell might start to transform to an immortal cancer cell (Elmore 
2007, Lee et al. 2010a, Hongmei 2012).  
2.5.2 Inhibitors of apoptosis regulates cellular homeostasis 
The pro-apoptotic stimulus can also be inhibited or modulated by cellular FLICE-
inhibitory proteins (c-FLIP), that are another DED-containing protein homologues to 
caspas-8 and capsase-10, however lacking the catalytic domain (Fuentes-Prior & 
Salvesen 2004, Safa 2012). Therefore FLIP function is reduced to recruitment to the 
DISC and from there regulate DR-mediated apoptosis by directly binding to the 
initiator caspase without its activation functioning as a death signaling antagonist 
(Moubarak et al. 2010). There are three mammalian FLIP isoforms, two short 
isoforms named c-FLIPS and c-FLIPR, which are potent caspase inhibitors and one 
long isoform named c-FLIPL that functions are still not completely understood (Irmler 
et al. 1997, Safa 2012). When c-FLIPL is overexpressed it competes with procaspase-
8 for the DED binding sites of FADD, inhibiting the DR-induced apoptosis. However, 
heterodimerisation of caspase-8 and c-FLIPL has shown to cause partial processing of 
the caspase resulting in a molecule that can induce pro-survival signaling pathways 
(Bagnoli et al. 2010). Studies have shown that c-FLIPL can activate Akt, extracellular 
signal-regulated kinase (ERK) and the nuclear factor-κB (NF-κB) transcription factors 
pathways, thereby stimulation of cell growth, differentiation and replication (Safa 
2012). On the other hand, activation of the NF-KB or Akt pathway correlates with an 
increased expression of FLIPL showing a complex crosstalk between death signaling 
and cell survival signaling pathways (Micheau et al. 2001, Wang et al. 2008, Urbano 
et al. 2014). Furthermore, knock-out mice lacking the FLIPL are more sensitive to 
extrinsic apoptotic stimulus, as cells derived from these animals are primed towards 
cell death (Yeh et al. 2000). Recent studies have shown that cancer cell can benefit 
from overexpressing FLIPL making them death receptor ligand TRIAL resistant (Sun 
et al. 2017a). Another important protein family that controls caspase activity are the 
inhibitors of apoptosis (IAP; Gyrd-Hansen & Meier 2010). These IAPs are proteins 
defined by having a baculovirus inhibitior of apoptosis protein repeat (BIR) domain 
that enables binding and inhibition of caspases. In mammalian cells, XIAP is the only 
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IAP that is able to directly bind and inhibit caspase activity; whereas cIAP1 and cIAP2 
functions more as scaffolds interacting with caspases not inhibiting (Eckelman et al. 
2006). Cells lacking XIAP are more sensitive to apoptotic stimulus; on the other hand 
cancer cells overexpressing IAPs can tolerate sever conditions, such as nutrient 
depravation, DNA damage and hypoxia without activating the apoptotic cascade 
(Gyrd-Hansen & Meier 2010, Elmore 2007). Understanding such crosstalk between 
two opposite cellular processes will unravel important features of cell homeostasis 
and cancer progression, with mechanisms enabling fast switches from survival to 
death or the other way around. Therefore, creating drugs that would specifically target 
cellular switches have become attractive drug candidates for cancer treatment (Dubrez 
et al. 2013). 
2.6 Nanomedicine for personalized therapy 
Cancer and cardiovascular disease is the number one cause of death in the western-
world and the World Health Organization (WHO) estimated that there will be over 15 
million new cases of cancer worldwide in 2020 (Wicki et al. 2015). In Finland there 
was around 34 122 new cancer cases in the year 2016 and the mortality rate was 
around one third of the affected population (Finnish Cancer Registry 2016). In the 
United States of America the ratio is quite similar as there was around 1 596 670 
diagnoses and 571 950 deaths from cancer in 2011 (Steichen et al. 2013). One of the 
major challenges in current cancer treatment is the lack of drug accumulation in target 
tissues and the dose-related toxicity as the administration of chemotherapy often 
include high systemic exposure leading towards unwanted side-effects (Allan & 
Travis 2005, Wicki et al. 2015). The therapeutic index is a term that describes how 
much drug is needed for the therapeutic effect compared to the dosage that causes 
toxicity (Muller & Milton 2012). Therefore, the development of targeted drug delivery 
systems are required in order to increase the therapeutic window and therefore reduce 
the side-effects of administered drugs (Meijerman et al. 2008, Copple et al. 2014).  
Nanomedicine is an emerging interdisciplinary field where nanotechnology and 
medicine combines in the pursuit of developing nanomaterials that could be used for 
personalized diagnostics, treatment, prevention and delivery of drug molecules to 
target tissue (Seigneuric et al. 2010, Rivera Gil et al. 2010 Kluenker et al. 2018). 
Nanoparticles have shown great potential as drug delivery vehicles due to low 
toxicity, high drug loading capacity, potential of bypassing biological barriers and 
tailor-made surface functionalization (Wagner et al. 2006, Seigneuric et al. 2010). 
Furthermore, nanoparticles can prolong the drug dissolution at the target site in order 
to obtain optimal therapeutic efficacy by keeping the drug molecule encapsulated and 
thereby preventing premature release (Sun et al. 2015). Functionalized nanoparticles 
with targeting ligands can be used for specific cell type internalization and thereby 
increase the therapeutic index and lowering the off-target effects (Tsai et al. 2009, 
Rosenholm et al. 2009, Zhang et al. 2018). There are thousands of publications on 
different nanoparticles for targeted drug delivery of both liposomal, polymeric and 
inorganic nanoparticles. However, there are only a few FDA clinically approved 
nanomedicine on the market such as Abraxane®, Doxil®, Lipoplatin®, Marqibo® 
(Venditto & Szoka 2013). This could at least partly be explained by manufacturing 
challenges such as upscaling of the production in a cost effective way, limited 
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available toxicity data on nanomaterials as well as bottlenecks in keeping the 
nanocarrier in a well-dispersed homogenous suspension (Wagner et al. 2006, 
Crookes-Goodson et al. 2008, Wicki et al. 2015). Some might even say that 
collaboration between academia and industry is still in their “infancy” and needs to 
be further developed in the pursuit of creating targeted drug systems that can be used 
in the clinics (Venditto & Szoka 2013). 
2.6.1 Definition of nanomaterials 
The definition of nanomaterials lies in the dimensions of the object being between 0.2 
nm to 100 nm, which is less than 0.0001 mm and as a reference a human hair is about 
0.1 mm in width (Lidén 2011). However, this definition is not absolute as there are 
different opinions regarding the dimensions of nanomaterials depending on what 
guidelines are being used (Maynard 2011). Regardless of the exact definition of these 
nanomaterials, quantum effects begin to dominate the properties of materials that have 
dimension less than 100 nm (Shrader-Frechette 2007, Karlsson et al. 2009). These 
tiny materials have different properties than their bulk counterpart, and one of the key 
reasons is because they have a larger surface area to volume ratio. Thus, allowing 
nanomaterials to be more reactive on both biological and chemical substances, which 
may be desirable, however also giving potentially adverse reactions (Chen et al. 2005, 
Chen et al 2006). Desirable properties of nanomaterials are that otherwise a non-
reactive material becomes reactive when produced in the nanoscale. These materials 
can gain new properties such as conductivity, oxidation potential, increased strength, 
optical transparency and magnetism. Qualities that are important in many different 
consumer products, for example, in sunscreen, cosmetics, CD players, hard discs and 
as protective coatings (Shrader-Frechette 2007). In nanomedicine it is important that 
these new materials are biocompatible and biodegradable as they would be used as 
targeted drug delivery systems or for diagnostic purpose, or even as a combinatory, 
teragnostic approach (Guo & Tan 2009, Jain 2012, Kluenker et al. 2018). 
2.6.2 Regulations of nanomaterials 
The regulation of nanomaterials is not a straight forward task, as the definition of 
nanomaterial is not standardized and may vary depending on what guidelines are 
being used (Lidén 2011, Maynard 2011). In the current Regulation of the European 
Parliament and of the Council of Europe on the Registration, Evaluation, 
Authorization and Restriction of Chemicals (REACH 2006) the word “nano” simply 
do not exist as a definition, which in turn causes some difficulties in categorizing these 
new materials in the European Union (EU) under the current regulations (Kimbrell 
2009). The European Commission has chosen to make use of existing legislation to 
regulate nanomaterial the so-called “incremental approach”, whereas the materials 
composition itself is the defining factor, regardless of the physical dimension of the 
material (Franco et al. 2007). Even though nanomaterials might have completely 
different properties than its bulk counterpart, for example gaining magnetic or 
oxidative properties (Shrader-Frechette 2007, Kroll et al. 2009). One possible reason 
for this approach is due to the reality that a change in legislation in such a way that 
nanomaterials would have a more extensive regulation is both technically demanding 
and politically problematic (Kimbrell 2007, Franco et al. 2007). The commission has 
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acknowledged that some adjustments needs to be made in REACH annexis in order 
to give a more specific framework regarding the requirements of nanomaterials and 
their risk assessments (Lidén 2011, Maynard 2011). 
An investigation done by Franco and colleagues in 2007 on the subject of how 
effective nanomaterials are regulated; showed that there are clear gaps in the 
legislation during that time as some nanomaterials were incorrectly classified in the 
Material Safety Data Sheets (MSDSs). The study evaluated the applicable regulations 
along the life cycle of three different products containing carbon nanoparticles; a 
badminton racket, a lubricant and a baseball club (Franco et al. 2007). One of the 
problems in the regulation of nanomaterials appears to be that the current methods 
available are sometimes insufficient to analyze and classify these new materials and 
their chemical and physiological properties (Kroll et al. 2009). Due to these 
uncertainties and the lack of toxicological data available, it becomes difficult to apply 
many of the current environmental laws to certain nanomaterials, such as the case with 
carbon nanotubes (Karlsson et al. 2008, 2009). The study done by Franco et al. 2007 
shows that it is often unclear whether nanomaterials are covered by the current 
legislation, which could lead to exposure to nanomaterials by either employers or 
consumers without their consent. This in turn rises the ethical questing about 
nanotechnology in the workplace, as there is still lack of clarity regarding the 
regulation of nanomaterials and the risk it may pose to workers (Schulte & Salamanca-
Buentello 2007). History has shown that "miracle materials" such as asbestos, 
mercury and dichlorodiphenyltrichloroethane (DDT) have serious health effects and 
probably some nanomaterials will also have adverse effect on both the environment 
and humans (Bartrip 2004, Kimbrell 2009).  
Nanomedicine on the other hand is under more strict supervision and regulation as its 
purpose is to either enhance the efficacy or reduce the toxicity of its agents that will 
be in clinical use (Crookes-Goodson et al. 2008). However, there is a clear need of 
harmonization regarding the regulations of nanomedicine as one regulatory agency 
might categorize a product as a medical devices and another agency might categorize 
the product as a medicinal product. In the EU the regulation applied depends largely 
on does the product contains at least one component in the nano-size (1-1000 nm) and 
is it purposely designed for clinical applications (Bremer-Hoffmann et al. 2018). The 
US Food and Drug Administration (FDA) has chosen a more case-by-case approach 
for the use of nanomaterials in products, according with specific legal standards that 
are applicable for each type of product (Pillai 2014, Bobo et al. 2016). Already in 
2016, there was around 51 FDA approved nanomedicine and another 77 products in 
clinical trials, and many of them are formulations made of micsells, liposomes or 
inorganic and metallic particles (Bobo et al. 2016). The trend in nanomedicine is 
going towards more complex materials that include actively targeting carriers and 
multi-functional theranostics that will further blur the boundaries of material 
categories making it even harder to classify these new materials (Pillai 2014, Bobo et 
al. 2016). In one study, regulatory agencies were asked to define which 
physiochemical properties is considered relevant for the preclinical characterization 
of nanomedicine that are not applicable to other pharmaceutical classes and based on 
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these answers; size and stability matters the most whereas density, surface charge and 
surface chemistry were less relevant (Figure 4; Bremer-Hoffmann et al. 2018). 
 
Figure 4. Relevance of physicochemical parameters for preclinical characterization of 
nanomedicine (adapted from Bremer-Hoffmann et al. 2018). 
 
2.6.3 Toxicity and environmental effects of nanoparticles  
Nanomaterials small dimensions make them more reactive than their bulk 
counterparts, they can penetrate deeper in to tissues and they can bind to protein and 
DNA, consequently there is an increased risk of toxicity and unwanted effects when 
using materials in the nanoscale (Shrader-Frechette 2007). However, the toxicity of 
nanoparticles does not entirely depend on the size, rather the combination of the 
physicochemical properties of the particle which depends on what materials are being 
used as well as the surface functionalization (Kroll et al. 2011). The increasing use of 
nanomaterials in pharmaceutics and consumer products causes nanomaterials to 
accumulate in the environment, where these new materials can have adverse reaction 
on the environment and on humans that can be hard to predict (Karlsson et al. 2009, 
Kroll et al. 2009). One of the contributing factors of nanoparticle accumulating in 
nature is due to the insufficient purification methods current wastewater treatment 
plants utilize. Most of the nanomaterials being consumed by human’s ends up in the 
sewage, from which they are not properly separated before released to the 
environment. The problem lies in the small size of nanomaterials as they do not settle 
down properly in aqueous solution and therefore cannot be sediment by gravity; as 
sedimentation is the current method to separate inorganic material from wastewater 
(Brar et al. 2010). The next step in the purification process is based on microorganisms 
that absorb the organic compounds, thus cleaning the sewage water even further. 
However, some of these nanoparticles have the ability to inhibit bacteria's growth and 
reduce their metabolism, which may degrade the purification capacity of the treatment 
plant even further (Brar et al. 2010, Ikuma et al. 2015).  
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For example, some nanoparticles are proven to be more toxic to different bacterium 
than the original bulk materials (Bondarenko et al. 2013). In Jiang et al. 2009 study, 
three different bacterium (Bacillus subtilis, Escherichia coli and Pseudomonas 
fluorescens) were used to investigate the toxicity of nano-scaled aluminum, silicon, 
titanium and zinc oxides. The result showed that nanoparticles made of zinc oxide 
were the most toxic as they killed 100% of all three bacterium. The aluminum oxide 
and silicon dioxide nanoparticles had both around 50% viability for all three 
bacterium. The bulk particles of aluminum oxide and silicon dioxide themselves were 
not toxic for the bacteria as no significant reduction in viability were detected when 
compared to the non-treated control samples. All bacterial samples that were given 
nanoparticles had a significantly lower viability compared to than of the untreated 
control samples. The only bulk material that had an effect was zinc oxide as it showed 
significant reduction in the viability of all three bacterial species (Jiang et al. 2009). 
Zinc oxide is a highly oxidative material as bulk and not surprisingly giving rise to 
some toxicity to the bacterium (Weibel et al. 2014). However, not all nanoparticles 
are toxic; for example aluminum and silica based nanoparticles are usually consider 
non-toxic to cells and safe for human consumption (Jiang et al. 2009, Harrison 2009, 
Kettiger et al. 2015). One should always remember that its is the dose that matters; as 
eating too much salt (sodium) for example could be dangerous for humans as well as 
drinking too much water (Yamashiro et al. 2013, Ha 2014).  
Furthermore, “bare” nanoparticles that are not functionalized are in generally more 
toxic to eukaryotic cells compared to e.g. coated metal particles that releases less 
harmful ions and functionalized particles are less prone to aggregation that can cause 
protein denaturation and DNA damage (Perreault et al. 2014, Srivastava et al. 2015, 
Huang et al. 2017). Environmental and toxicological studies of different sized 
particles shows that some nanoparticles are toxic to bacteria, algae, invertebrates and 
mammals (Handy 2008). Especially zinc oxide nanoparticles have been proved to be 
highly toxic for the fresh water flea Daphnia magna, whereas aluminum based 
nanoparticles were least harmful to the water flea (Zhu et al. 2009). In addition, D. 
magna could absorb nanoparticles that were accumulated in the digestive system, 
enabling the nanoparticles to be transferred to the next trophic level (Zhu et al. 2010). 
In the experiment performed by Zhu et al. 2010 the fresh water flea was exposed to 
titanium dioxide nanoparticles for one day and then the D. magna was transferred to 
an aquarium to be consumed by Zebrafishes as food. The result showed that the 
nanoparticle could be taken up by the fresh water flea which was transferred to the 
next tropic level detected as particle accumulation in the Zebrafish (Zhu et al. 2009, 
2010). Taken together, nanoparticles can be toxic to animals and humans and that they 
can be transferred from lower trophic level to higher levels, indicating that some 
precautions in the development of nanomaterials are warranted. However the toxicity 
of these materials should not be generalized, as the size by itself is not the only 
affecting factor, rather consider each combination of the material with its specific 
surface charge, porosity, density and functionalization on a case-by-case manner 
(Kroll et al. 2011, Pillai 2014, Srivastava et al. 2015). 
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2.6.4 Mesoporous silica nanoparticles as targeted drug delivery  
Inorganic silica based nanoparticles have been receiving increasing attention in the 
field of targeted drug delivery systems because they are considered non-toxic and 
biocompatible as silica degrades in aqueous environment to different species of silica 
acid and ultimately gets excreted via the urine (Hao et al. 2012, Kettiger et al. 2015). 
There are roughly two ways of producing nanomaterials; either the top-down or the 
bottom-up approach where both methods have their benefits and downfalls 
(Hoffmann et al. 2006, Guo & Tan 2009). The top-down approach starts with building 
materials that have larger dimensions than the final product which means in practice 
that the materials undergoes physical stresses in order to be reduced in size. This in 
turn might lead to surface imperfections as well as the top-down method is not cost 
efficient as some of the raw materials goes to waste during production (Guo & Tan 
2009). The bottom-up method starts by introducing smaller building blocks in solution 
which then transforms to the final product, leading to less defects in a more cost- and 
material-efficient way (Huang et al. 2008). However, scaling up the bottom-up 
methods remains a major challenge, as variations in pH, temperature and mixing ratios 
may influence the structure of the final product (Desai 2012). There are different 
bottom-up methods such as co-precipitation, template synthesis and sol-gel method 
where the building blocks are often copolymers, colloids and liquid crystals (Brinker 
& Scherer 1990, Huang et al. 2008, Guo & Tan 2009). Synthesis of moderate size 
(250-300 nm) porous silica nanoparticles by the sol-gel method has some clear 
advantages as it enables delicate control of particle dimensions, which has a clear 
therapeutic benefit as smaller particles tend to be unspecifically internalized and larger 
particles tend to aggregate in biological systems (Rosenholm et al. 2006, 2008, 2009, 
Shang et al. 2014). 
Mesoporous silica nanoparticles (MSNs) are unique in the way that they have tunable 
ordered repetitive mesostructures of pores in the range of 2-10 nm and that these 
particles can be synthetized in various sizes and shapes (Liu et al. 2015, Kresge et al. 
1992). Mesoporous silica materials were first discovered in the early 1990s by Mobile 
Oil Company using surfactants as structure directing agents together with inorganic 
materials that can be deposited through hydrolysis and condensation using the sol-gel 
method (Kresge et al. 1992, Beck et al. 1992). The porous silica structures are 
revealed after the removal of the surfactant by either chemical extraction or thermal 
calcination. In short, the synthesis contains four main components: source of silica, 
structure-directing agent (surfactants), solvent (often methanol or ethanol), and a 
catalyst (often sodium). The formation depends on two main phenomena: the ability 
of the surfactant to form micelles in liquid and the ability of the inorganic material 
(silica) to condensate in order to form stable structures (Hoffman et al. 2006, Wan & 
Zhao 2007). The shape and size of the micelles defines the size of the particles 
whereas the mesoporous are mostly governed by the surfactant used and its 
concentration as well as pH, temperature and presence of other components 
(Ducheyne et al. 2015). Rendering the variation of different MSNs that can be 
produced to astronomical and therefore numerous variables need to be taken in 
account for when designing and synthetizing MSNs for targeted drug delivery 
systems. In the pharmaceutical industry, Good Manufacturing Practices (GMPs) 
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guidelines have been developed for the production of medicinal products that will be 
used by humans in order for the final product to be consistent and safe (Adamo et al. 
2012, Gouveia et al. 2015). There are laboratory products in the market containing 
nanoparticles that have been produced using GMPs, for example, NanoParticle 
Fluorescent Calibration Slide (Grace Bio-Labs inc., Bend, Oregon, USA) designed to 
be used for microarrays scanners. However, highly detailed protocol standards are not 
always feasible in academic laboratory conditions that might account for some 
variation in the synthetized product (Desai 2012, Baer et al. 2018).  
 
2.6.5 Targeting strategies for MSNs  
Targeting approached can be classified in to either active or passive targeting. In the 
passive targeting, non-functionalized particles would quickly be removed from the 
blood circulation by macrophages through the process of opsonization, where the 
particles accumulate in the liver and spleen for clearance (Owens & Peppas 2006). 
This accumulation can be utilized when treating hepatic and spleen disorders such as 
liver fibrosis, hepatocellular carcinomas or Hodgkin’s and non-Hodgkin’s 
lymphomas (Hillaireau & Couvreur 2009). Non-functionalized particles have also 
been observed to accumulate at tumor sites elsewhere in the body, due to enhanced 
permeability and retention effect (EPR) which is a consequence of leaky and 
fenestrated blood vessels around majority of tumors (Gerlowski & Jain 1986, 
Matsumura & Maeda 1986). However, passive targeting that utilizes the EPR effect 
might not be sufficient in all cancer cases combined with the possible off-targeting 
effects that might have a negative impact on the patient’s wellbeing (Bae & Park 2011, 
Bazak et al. 2014). Therefore, functionalizing the particle surface with an active 
targeting ligand could further enhance the drug accumulation at the target site and 
minimize possible side effects (Bae & Park 2011). Such functionalization can be 
achieved by covalently attaching a cancer specific targeting ligand in order to increase 
the particle endocytosis in the tumor cells with minimal uptake in healthy cells (Figure 
5; Rosenholm et al. 2006, 2008a&b, 2009a&b, 2010).  
 
 
Figure 5. Schematic representation of the key concept of MSNs targeted drug delivery. 
Utilizing cancer specific traits such as high folate receptor or glucose transporter expression in order 
to have increased particle internalization in target cells with minimal uptake in healthy cells for 
minimizing side effects of the drug. Improved efficacy can be achieved by using drugs that 
intervenes more pronounced in cancer cells than healthy cells, for example, celastrol that kills fast 
dividing cells through destabilizing the mitotic spindle.  
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For example, one common trait of many cancer cells are that they express folate 
receptors in much higher amounts than most normal tissues (Parker et al. 2005). 
Therefore utilizing folic acid as a small molecule targeting ligand, which is a 
synthetically produced vitamin B9, it is possible to achieve targeted drug delivery 
towards folate receptor expressing tumors (Leamon & Low 2001, Leamon & Reddy 
2004). Cancer cells with high folate receptor expression would internalize these 
nanoparticles through receptor-mediated endocytosis and as a consequence they 
would internalize much higher amounts of drug-loaded particles than the healthy cells; 
giving rise to high drug concentrations at the tumor site with potentially lower off-
target effects (Rosenholm et al. 2009, Rosenholm et al. 2010a&b, Porta et al. 2013). 
Other small molecules that can be utilized for targeting strategies are for example, 
carbohydrates designed for interacting with lectin receptors at the surface of cells 
(Carrillo-Conde et al. 2011). Sugar targeting strategies may include; mannose- or 
galactose-functionalized particles that can be internalized through mannose or 
asialoglycoprotein receptor-mediated endocytosis by macrophages or with glucose 
(Gluc) conjugated particles through glucose transporters (GLUT) that are commonly 
overexpressed in cancer cells (Brevet et al. 2009, Sonoke et al. 2011, Gary-Bobo et 
al. 2012, Li et al. 2014). Active targeting strategies might also include covalently 
attaching peptides, antibodies and nucleic acid based aptamers to the nanoparticle 
surface (Kue et al. 2016). Targeting peptides such as arginine-glycerin-aspartic acid 
(RGD) can be used for binding with αυβ3 integrin receptor at the tumor cell surface 
in order to archive targeted drug delivery (Xiao et al. 2014). However, using small 
molecules for targeting ligands have some advantages over peptides and antibodies 
due to their stability, ease of conjugation, and relative low cost (Kue et al. 2016).  
Antibodies on the other hand has the benefit of targeting specific antigens at the tumor 
cell surface giving rise to higher specificity than small molecules (Fosgerau & 
Hoffmann 2015). Folate for example, which is abundant in the diet, can compete with 
the ligand-modified delivery vehicle when circulating in the bloodstream and 
therefore lower the desired efficacy (Attarwala 2010). Anti-HER2 monoclonal 
antibody conjugated MSNs have been developed for targeting breast cancer cells as 
well as an anti-EGFR functionalized particle for the treatment of an EGFR mutated 
lung cancer (Tsai et al. 2009, Wang et al. 2016). However, some of the major 
drawback from antibody based targeted drug delivery systems is due to the potential 
unwanted immunologic reaction, as well as the risk of the ligand being degraded in 
the body combined with the difficulty in conjugating the antibody to the delivery 
system at the desired amino acid site (Tsai et al. 2009, Wang et al. 2016). Aptamers 
on the other hand are therapeutic oligonucleotides that are built of single stranded 
DNA or RNA, which forms three-dimensional structures with high affinity and 
specificity towards proteins in similar manners as monoclonal antibodies. There are 
some length limitations of these aptamers as sequences longer than 60 nucleotides are 
not feasible to produce under the current methods and this can lead to some restrictions 
in what protein can be targeted (Ray & White 2010). Due to these pros and cons of 
different targeting strategies, active targeting that utilizes small molecules could be 
considered as the first choice to start with in an academic project as it would most 
likely be cheaper and easier to execute. 
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2.6.6 Cellular internalization and interaction of MSNs 
Each living cell is surrounded by a lipid bilayer (LB) called the cell membrane that 
protects and separates the cell from the surrounding (Wilbrandt 1935). The cell 
membrane functions as a semi-permeable membrane that allows diffusion of small 
molecules and lipophilic signaling molecules and together with its receptors and 
transporters maintains the cells chemical composition (Goñi 2014). The size, shape 
and charge of the extracellular molecule determines which internalization pathway 
will be employed by the cell which is also the case for nanoparticles (Verma & 
Stellacci 2010, Albanese et al. 2012). Larger particles are internalized via 
phagocytosis, whereas particles of moderate size of a few hundred nm can be taken 
up by several mechanisms whereas small particles of around 10 nm are more likely to 
unspecifically penetrate the cell membrane (Figure 6; Kou et al. 2013). The amount 
of particles internalized may vary depending on the cell type being investigated and 
particle size and form, for example, HeLa cells seems to favor spherically shaped 50 
nm sized MSNs whereas human melanoma cells favor rod shaped particles of 420 nm 
size (Lu et al. 2009, Barua & Mitragotri 2014). The surface charge of the nanoparticles 
influences the uptake kinetics as positively charged particles are usually internalized 
in higher quantities than negatively charged (Chung et al. 2007). The surface charge 
of the particles also seems to determine the intracellular distribution; as positively 
charged particles possesses the ability to escape endosomes whereas acidic or 
negative/neutrally charged particles usually retains in lysosomes designated for 
degradation (Yue et al. 2011, Baltazar et al. 2012). The undelaying mechanism of this 
endosomal escape is probably due to of the extra positive charge of the nanoparticle 
is being balanced by chloride ions influx that results in an increased ionic strength. 
This in turn leads to increase volume of water inside the endosome followed by 
swelling and finally rupture of the membrane, a phenomenon known as “proton-
sponge” effect that results in the escape of the nanoparticle from the endosome 
(Godbey et al. 1999, Rosenholm et al. 2009, Varkouhi et al. 2011). 
Figure 6. Schematic representation of nanoparticle internalization pathways. a) Larger 
particles are internalized via phagocytosis mostly by macrophages through actin-based mechanism. 
Moderate sized nanoparticles can be internalized through different mechanism for example; b) 
Clathrin-mediated endocytosis, c) caveolae-mediated endocytosis or d) by engulfing particles and 
the extracellular milieu by macropinocytosis. There are other e) non-specific internalizations that 
are clathrin and caveolin independent and tiny particles can unspecifically pass through membranes 
by f) trans-location (adapted from Hillaireau & Couvreur 2009, Kou et al. 2013). 
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The particles surface balance between hydrophobicity and hydrophilicity plays an 
important role in stability and internalization. Hydrophobic particles encourage 
internalization as the cell membrane is made of lipids having high affinity towards 
each other (Nam et al. 2009). However, for the particle to be dispersed in aqueous 
solution such as in the blood stream and to be released to the cytoplasm it is equally 
important to have hydrophilic properties, as highly hydrophobic particles tend to 
aggregates and stay at the cell surface (Samadi Moghaddam et al. 2015). Therefore, 
by functionalizing the inorganic hydrophobic MSN with organic water-soluble 
polymer such as polyethyleneimine (PEI) or polyethylene glycol (PEG) it is possible 
to match these criteria for optimal internalization and intracellular distribution 
(Rosenholm et al. 2009, Lee et al. 2010b). 
2.6.7 Biocompatibility and bio-distribution of MSNs 
In order to evaluate the potential clinical use of MSNs as targeted drug delivery 
systems it is imperative to study not only efficacy or cellular internalization but also 
the biocompability and bio-distribution both in vitro and in vivo. As one of the main 
challenges in targeted drug delivery is to achieve sufficient amount of drug to the 
target tissue with minimal off-targeting effects (Sanhai et al. 2008, Bae & Park 2011). 
This is of special importance in cancer therapies, were the treatment has serious side-
effects on the patients such as hair loss, weight loss, anemia, general nausea and pain 
(Farokhzad & Langer 2009, Ramirez et al. 2009). MSNs have shown considerable 
potential as drug carrier due to high loading capacity and low toxicity as silica-based 
materials are biodegradable and therefore generally considered safe (Harrison 2009). 
By intravenous (i.v.) injections, it is possible to administer directly to the bloodstream 
where the nanoparticles can either use passive targeting or utilize active targeting in 
order to seek the tumor cells (Fu et al. 2013). With systemic administration, it is 
possible to bypass some of the hurdles orally ingested drugs might encounter such as, 
as low pH, enzymes that might metabolize the drug and an intestinal layer that needs 
to be penetrated (Jain 1999, Sriraman et al. 2014). However, nanoparticles in the 
bloodstream will be covered in plasma proteins (opsonins) that favor phagocytosis by 
macrophages in the spleen and liver that might limit the amount of particles reaching 
the target site (Owens & Peppas 2006). Systemic administration might also lead to 
accumulation of the drug molecule in healthy tissues and organs leading to unwanted 
side effects (Palumbo et al. 2013). Furthermore, if the tumors resides in the brain the 
particle most also penetrate the blood-brain-barrier (BBB) which can be a challenge, 
as macromolecules in general are not allowed to enter the brain (Ballabh et al. 2004). 
In order to overcome such obstacles; both the administration route and the 
nanoparticle design should carefully be considered in order for the cargo to be released 
at the target site. Studies done on healthy mice shows that the bio-distribution after 
i.v. injection of MSNs accumulates in the liver, kidney and urine bladder whereas 
some of the particles were excreted through the renal route (Liu et al. 2013, Fu et al. 
2013). However, a sick tumor bearing mice phenotype is different from a healthy 
mouse, consequently MSNs accumulates in the tumor area due to the EPR effect of 
the leaky and fenestrated blood vessels (Matsumura & Maeda 1986, Park & Park 
2016). Particles with a hydrodynamic diameter (HD) of a few nm are so small that 
they can pass the glomerulus in the kidneys and therefore be cleared from the 
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circulation via the urine (Figure 7; Barua & Mitragotri 2014, Shang et al. 2014). 
Particles larger than 8 nm cannot easily pass through the glomerulus in the kidney as 
the fenestrations are in the size range of 2-8 nm; however rod-shaped particles with a 
diameter less than 6 nm can still pass through due to their elongated shape. The renal 
clearance can be enchanted even with larger particles if the material composition is 
biodegradable so that the nanoparticle can dissociate into small clearable fragments 
(Liu et al. 2013). On the other hand, particles larger than 200 nm are at risk of being 
phagocytosed by macrophages in the liver that could influence the final bio-
distribution (Hillaireau & Couvreur 2009, Owens & Peppas 2006). Functionalization 
plays also an important role as PEGylated MSNs with the intermediate size of 70 nm 
where phagocytosed by macrophages in the liver, spleen and lungs (Lee et al. 2010b). 
Another mice study showed that injected PEI functionalized MSNs accumulated at 
the tumor site with around 10%, whereas the liver accumulated around 27%, and the 
lungs had about 15%, with ~14% in the spleen and that the kidneys had around 4% of 
the circulating particles (Park & Park 2016). Therefore, functionalization, material 
composition, degradation profile and size do matter for targeted drug delivery and that 
the desired accumulation at the tumor site can be further increased by adding an active 
targeting ligand at the surface of the MSNs. 
 
Figure 7. Schematic representation of ideal targeting strategy. a) Clinical use of clearable 
nanoparticles where the diseased tissue specifically internalizes the particles and the off-targeting 
particles are rapidly cleared from the circulation through renal clearance. b) Structure of the kidney 
corpuscle where c) glomerular filtration is a nano scale phenomenon. The capillary wall inside the 
glomerulus is made of three layers: fenestrated endothelium, glomerular basement membrane and 
podocyte extensions of epithelial cells (Liu et al. 2013). 
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2.6.8 Drug incorporation and drug release of MSNs 
Mesoporous silica nanoparticles have shown considerable potential as targeted drug 
delivery systems because of their unique properties e.g. high loading degrees of drug 
molecules, controlled drug release kinetics and the possibility of various targeting 
ligand functionalization (Liong et al. 2008, Wang 2009, Vivero-Escoto et al. 2010). 
By loading drugs inside the porous structures of the particles it is possible to have 
controlled intracellular release of hydrophobic cargo that otherwise would not have 
reached to the target tissues that could have resulted in a premature release (Vallet-
Regí et al. 2007, Kwon et al. 2013, Bharti et al. 2015). Several factors influence drug 
loading and release kinetics of MSNs such as particle morphology, pore size, chemical 
composition, functionalization, physiological environment, and the properties of the 
drug being incorporated to the particle as well as the drug loading method. 
(Rosenholm et al. 2008a, Hao et al. 2012, Vallet-Regí et al. 2017 Zhou et al. 2018).  
Currently, the two most common methods for drug loading to the MSNs is either by 
physical adsorption of a highly saturated drug solution to the porous surface or by 
covalently conjugating the molecule to the particle surface (Popat et al. 2011). The 
process of impregnating the drug molecule to the pore walls can be facilitated by 
selecting a solvent that has low affinity to the drug, thus favoring the drug adsorption 
towards the silica material (Rosenholm & Lindén 2008, Andersson et al. 2004). For 
example, by using a hydrophobic solvent such as cyclohexane with a hydrophobic 
drug or an aqueous solution for water-soluble drugs (Rosenholm et al. 2009, 
Rosenholm & Lindén 2008). Furthermore, the charge of both the drug molecule and 
MSNs surface influences drug adsorption. The non-functionalized MSNs have a 
negative charge and will attract positively charged drug molecules as the PEI 
functionalized particles have a positive charge which will allow loading of negatively 
charged drug molecules (Andersson et al. 2004). By covalently conjugating a drug 
molecule in the porous structure it is possible to have an enzymatic driven drug release 
inside the cells without undesired leaking during the journey to the target site (Mortera 
et al. 2009, Popat et al. 2012, Yuan et al. 2013). However, careful considerations need 
to be accounted for when covalently attaching drug molecules on the particle as this 
might allosterically change the configuration of the molecule to its inactive form 
(Yuan et al. 2013). The drug inside the MSNs can also be released by simple diffusion, 
temperature-driven release, pH driven or photo-induced release (Figure 8). The 
release mechanism and kinetics of MSNs depends on drug solubility and particle 
properties, for example, water-soluble drugs are mainly released by diffusion, whereas 
hydrophobic drugs are usually released by degradation of the carrier (Costa and Lobo 
2001, von Haartman et al. 2016). Spherical nanoparticles have shown to have faster 
dissolution rates than rod shaped particles, which is due to their relative larger outer 
surface area (Hao et al. 2012). Furthermore, the endosomal release of the drug-loaded 
nanoparticle can be facilitated by the proton-sponge effect (Godbey et al. 1999, 
Varkouhi et al. 2011). Particle functionalization plays also an important role in drug 
dissolution from the nanoparticles; for example, PEI branching have been shown to 
function as a “molecular gate” preventing premature release of drug molecule outside 
target cells (Zhou et al. 2018, Rosenholm et al. 2008b, Mamaeva et al. 2016). 
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Figure 8. Schematic presentation showing receptor mediated particle internalization and 
different drug release mechanisms from MSNs. The drug cargo can be released through simple 
diffusion in the case of water-soluble drugs or as a consequent of a decrease of pH in the late 
endosome resulting in an endosomal release of the drug carrier or by photo-release induced by an 
external laser or by degradation in the lysosome or by erosion of the particle. 
 
In addition, drug-loading degree can influence the release kinetics; having a high 
loading-degree increases the formation of crystalline form of the drug inside the 
particle (Popat et al. 2011). As drugs in the crystalline form have lower dissolution 
rate than drugs in the amorphous form, therefore having the molecule in the non-
crystalline form might be of interest for increasing drug efficacy (Maghsoodi 2015). 
Furthermore, pore size plays an important role as pores smaller than 10 nm in diameter 
confines the drug molecule inside the particle preventing crystallization of the 
molecule, therefore keeping the drug in an amorphous state (Zhou et al. 2018). It is 
due to these highly variable design possibilities of MSNs and their high drug loading 
capabilities that makes them potential drug delivery systems for various diseases and 
conditions. 
2.7 Celastrol - a natural compound as potential drug candidate 
Natural compounds have lately received attention in the pharmaceutical field due to 
limitations of synthetized drug molecules that currently can be manufactured. For 
example, cost efficiently synthetizing complex chiral molecules in larger quantities, 
is still a challenge (Atanasov et al. 2015). Natural compounds on the other hand, can 
be very complex molecules made by living organism that are evolutionary optimized 
for having a biological functions or activity (Beutler 2009). The natural compound 
celastrol is a pentacyclic triterpene extracted from the traditional Chinese medicinal 
plant Thunder God Vine (Tripterygium wilfordii Hook.F.) that have been used for 
centuries against fewer, rheumatics and other inflammations (Westerheide et al. 2004, 
Salminen et al. 2010). Celastrol has the ability of manipulating cellular homeostasis 
depending on the amount being administered and what cell type is affected (Figure 
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9). Celastrol reacts to the nucleophilic thiol groups of the amino acid cysteine forming 
covalent Michael adducts, thereby changing the structure and function of the protein 
(Salminen et al. 2010). In lower concentration, celastrol activates the cellular heat 
shock response (HSR) in similar manners as heat stress by turning on the heat shock 
transcription factor 1 (HSF1), which leads to the increased expression of molecular 
chaperones called heat shock proteins (HSPs; Chow et al. 2007, Westerheide et al. 
2004). Molecular chaperons are important in protein quality control and folding, as 
well as in the protection of cells from different forms of proteotoxic stress, such as 
heat shock, oxidative stress, heavy metals and chemicals (Westerheide et al. 2004, 
Trott et al. 2008). Many neurodegenerative diseases, such as Huntington’s and 
Kennedy’s disease, are characterized by protein aggregates that have a toxic effect on 
cells. These polyglutamine aggregates are also considered the underlying cause for 
the initiation and progression of other neurodegenerative diseases such as Alzheimer’s 
and Parkinson’s disease (Adachi et al. 2009, Leak et al. 2014). The 70-kDa heat shock 
protein (Hsp70) assist a wide range of protein folding processes such as the assembly 
of newly synthesized proteins as well as the refolding of misfolded proteins (Mayer 
& Bukau 2005). An increase in expression of molecular chaperones has been found 
to reduce the toxicity of protein aggregates and therefore up-regulation of molecular 
chaperones is of pharmacological interest in treating diseases characterized by 
accelerated protein aggregation (Dubey et al. 2015). However, recent studies done on 
yeast has shown that the molecular chaperone Hsp70 functions as an negative 
feedback loop of its transcription factor HSF1, where a sudden increase in the 
expression of Hsp70 as an consequence of proteotoxic stress leads to the deactivation 
of HSF1 turning off the transcription of the molecular chaperone (Krakowiak et al. 
2018). Therefore, pharmacologically activating the heat shock response by an steady 
release kinetics without triggering the negative feedback loop could be beneficial in 
treating diseases associated with protein aggregates such as Alzheimer’s and 
Parkinson’s.  
Celastrol have recently gained medical interest as a possible therapeutics to be used 
for inducing the heat shock response (Cascão et al. 2017). However, the therapeutic 
window for the use of celastrol is narrow, because of low water solubility and due to 
higher concentrations induces toxicity by intervening with cell division (Li et al. 
2012). Celastrols ability to induce cell death is through destabilizing the mitotic 
spindle of dividing cells and by disrupting topoisomerase II function that ultimately 
leads to DNA fragmentation and cell death (Jo et al. 2010). However, by targeted drug 
delivery, it would be possible to increasing the local concentration of celastrol in 
cancer cells with high cell division in order to kill these fast growing cells through 
mitotic catastrophe (Piras & Piras 1975). On the other hand, chemically inducing the 
heat shock response in neuronal cells of Alzhaimers patients it would be possible 
protects the brain from accumulating further harmful protein aggregates (Salminen et 
al. 2010, Cascão et al. 2017). Taking together, targeting celastrol to specific cell types 
by carrier systems could significantly lower the amount of drug concentration needed 
to be administered to the patients for inducing desired kinetics of the heat shock 
response and consequently minimize the associated toxic effects.  
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Figure 9. Celastrols unique property of modulating cellular homeostasis. Low concentrations 
induces the heat shock response increasing the amount of molecular chaperones thus protects the 
cells from harmful protein aggregates. High concentrations of celastrol in dividing cells destabilize 
the microtubule leading to mitotic catastrophe and cell death. Therefore, targeting celastrol to 
specific cell types by carrier systems could be beneficial in diseases that originate from proteotoxic 
stresses. 
 
2.8 Quantitative bioimage analytics for personalized diagnostics 
Historically Antony van Leeuwenhoek (1632-1723) is considered one of the pioneers 
in the field of microcopy where he gave detailed descriptions of protozoans in 
different environments with his hand made microscope (Lane 2015). In the past, 
microscopy was a qualitative method; however as the digitalization made several 
advances also in digital microscopy it is nowadays possible to also extract quantitative 
information from qualitative images (Nat Methods 2012). Today, bioimaging has 
grown to become one of the key methodologies in biomedical research. New imaging 
techniques emerges that uses ever-higher resolution combined with faster than before 
throughput measurements producing large multidimensional images (Kankaanpää et 
al. 2012). However, manual quantification still often used in order to transform the 
vast arrays of image data produced into meaningful information. Nowadays there are 
numerous general image analysis software’s available, however it is often necessary 
to develop tailor made analytical workflows for each specific biological purpose 
which can be challenging as most cell biologist do not have an programming 
background (Nat Methods 2012, Kankaanpää et al. 2012, Carpenter et al. 2012).  
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Figure 10. Automated image analysis for identifying hemorrhage centers in human retinas. 
The left column depicts an example of color fundus images of a human retina taken from the Kaggle 
dataset. The middle column shows reference hemorrhage center locations depicted as white dots. 
The right column shows pixel probability maps obtained by deep learning network architectures 
image analysis (Van Grinsven et al. 2015). 
There are a few user-friendly image analysis software available such as ImageJ, Fiji, 
CellProfiler, BioImageXD and Icy that can be implemented without advanced 
programming skills in order to acquire quantitative data (Hartig 2013, Eliceiri et al. 
2012). Computerized image analysis can also gain new information, such as size 
distribution, intensity quantifications and co-localization that would manually be too 
laborious to execute. BioImageXD for example, supports true 3D data analysis that 
include flexible visualization and easy-to-use batch processing that requires no 
programming skills (Kankaanpää et al. 2012). BioImageXD has been used in many 
publications within the biomedical research field ranging from virology and 
nanoparticle internalization to cancer medicine and drug development (Upla et al. 
2004, Karjalainen et al. 2008, Sukumaran et al. 2012). Such computerized image 
quantification workflows could also open up possibilities for automated diagnostics 
and personalized medicine to fight against different forms of diseases such as cancer 
and neurodegenerative disorders (Kim et al. 2011, Oxtoby et al. 2017). For example, 
it would be possible to analyze the amount of protein aggregates in brain tissue or the 
relative amount of heat shock proteins expressed in traumatized organs such as the 
heart or liver. There are already some image analysis currently used in clinics, for 
example, identifying anatomical changes in mammography of patient with possible 
breast cancer. The method is based on texture analysis of mammograms where the 
clinician have selected the region of interest, then the computer automatically 
discriminates between benign and malignant clusters based on the preset classification 
schemes (Kim et al. 2011). In another study, automated image analysis was used in 
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combination with computer learning in order to identify hemorrhage centers in human 
retinas (Figure 10). Demonstrating that in the future, it would be possible of 
combining automated image analysis with deep learning of clinical data for even faster 
personalized diagnostics with less need of human operation and interpretation (Van 
Grinsven et al. 2015). 
2.9 Funding and patenting challenges in academic research  
Funding opportunities in the United states of America (USA) has changed during the 
past 50 years from previously mostly federal funded research to a more mixed source 
of finance with also business-funded basis (Edwards & Roy 2017). This has led to a hypercompetitive environment for academics seeking funding from government 
agencies such as National Institutes of Health (NIH), Centers for Disease Control and 
Prevention (CDC) that creates pressure for researchers to “cut corners” leading 
towards possible unethical behavior. Because of the increased competition and the 
demise of academic positions, many PhD graduates are selecting careers elsewhere in 
government or in industry (Abbott et al. 2010, Stephan 2012a&b, Edwards & Roy 
2017). Obtaining funding is also an age-related problem as young scientists with novel 
ideas might be rejected, as these new ideas might not fit in the current accepted view. 
This happened to the Nobel Prize winners Drs. Barry Marshall and Robin Warren in 
the 1980s when they tried presenting their findings that ulceration is primarily an 
infectious disease at a gastroenterology meeting in Australia, as their abstract was 
rejected because at that time ulcers were believed to be a result from stress (Shuchman 
2018).  
During the last decades, revolutionary advances in gene therapy, stem cell research, 
proteomics, genomics and nanotechnology have shown that there is a need of 
reconstructing traditional basic science and clinical research in order to facilitate 
translational research that would give rise to novel effective therapeutics (Homer-
Vanniasinkam & Tsui 2012). The academic culture need to start valuing patenting and 
commercialization activity as important merit for career advancement as publishing 
and teaching. As industrial research laboratories are in a decline in the US and 
universities need to play a more central role in technology transfer for facilitating new 
discoveries and inventions (Sanberg et al. 2014). The US Department of Commerce’s 
report in 2012 lists that there is a need to “speed the movement of ideas from basic 
science labs to commercial application”. Innovations are crucial in the modern 
knowledge-centered economic growth of welfare countries with high salaries and raw 
material shortage combined with an ageing population and its associated problems 
(Mainzer 2011, Lunenfeld 2013, Sanberg et al. 2014). Therefore, integration of 
different scientific fields with medicine is crucial in order to response to 
transdisciplinary global problems. The Carl von Linde-Academy in Germany is prime 
example of such innovation center; distinguished for its combination of natural 
science, medicine, and life sciences platforms with interdisciplinary research projects 
and courses across all faculties. The mission of the Carl von Linde-Academy is to find 
and support creative potentials of the university, a vision strongly supported by the 
German state and society (Mainzer 2011).  
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Figure 11. Research and development (R&D) efficiencies of research-based pharmaceutical 
companies during the years 2006–2014. Total number of new molecular entities (NMEs) 
approved by the Food and Drug Administration (FDA) compared to the total R&D expenditure per 
company. The size of the bubble illustrates the R&D intensity calculated from R&D expenditure 
divided with total sales shown in percentages. Calculation that the accumulative cost per approved 
drug is approximately 3 billion USD (Schuhmacher et al. 2016). 
One could argue that the main goal of biomedical research is to ensure that inventions 
such as a new therapy, device or method would be clinically implemented as the initial 
motivation for the researcher often is based on trying to solve a problem and cancer 
is one prime example of such situation (Heus et al. 2017). However, the development 
of an invention can be very expensive, for example, clinical testing of a drug typically 
have an accumulative cost of millions of US dollars and therefore it is crucial to 
protect intellectual property rights (IPR) in order to have a fair return of the initial 
investment (Figure 11; Heus et al. 2017, Schuhmacher et al. 2016). The historical cost 
per approved drug has gone from 1 billion US dollars to today’s estimation of more 
than 3 billion dollars (Schuhmacher et al. 2016). Aspects that is not generally 
acknowledged among academic researchers as their model of operation differs from 
the business model of a pharmaceutic company, and as an consequents universities 
often have little founding left for product development and patenting (Heus et al. 
2017). In the US it is estimated that 1 million dollars of federal funding give rise to 10 
new publication but only 0.2 new patents, rendering the impact of state funded 
research to relatively small (Jacob & Lefgren 2011). On the other hand, funding 
agencies are starting to place emphasis also on translational research as separate 
funding entities are being developed; NIH’s National Center for Advancing 
Translational Sciences is one example that will help universities build long-term 
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partnerships with industry (Sanberg et al. 2014). Therefore, supporting 
interdisciplinary PhD programs with integrated IPR funding combined with an 
established industrial network could facilitate innovations and create new effective 
therapies that could benefit patients and society as the cost of R&D is in millions 
(Figure 12; Hammerstedt & Blach 2008). 
 
  
Figure 12. Graphic representation of the relative progress of original academic ideas through 
product development to final profit making product (Hammerstedt & Blach 2008). 
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3. AIM OF THE STUDY 
The collective aim of this thesis was to create new innovative drug delivery systems 
that could be used in the future to fight cancer, and to develop imaging modalities for 
detecting the drug efficacy in target cells. Mesoporous silica nanoparticles (MSN) 
were chosen as delivery system owing to their high loading capabiliaty of 
hydrophobic molecules and due to their modular design with endless functionalization 
possibilities. By combining John Eriksson’s labs experience in cell death and survial 
with Kid Törnqvist’s group’s cell signaling knowledge together with Jessica 
Rosenholm’s BioNanoMaterials group it was possible to create MSNs for targeted 
drug delivery that can be used for controlling the cellular homeostasis. Furthermore, 
this collaboration has opened up the possibility of evaluating different targeting 
strategies and their efficacy towards cancer cells. 
The first specific aim was to exploit cancer cells increased metabolism in order to 
achieve targeted drug delivery. Since cancerous cells have much faster metabolic rate 
than most normal healthy cells they take up glucose at significantly higher rates, 
potentially allowing for selective internalization of glucose-conjugated nanoparticles. 
By loading the nanoparticle with celastrol, an active ingredient of the traditional 
Chinese medicinal plant Tripterygium Wilfordii, it should be possible to specifically 
target cancer cells and induces apoptosis (I). 
The second specific aim was to achieve target selectivity by functionalizing the 
nanoparticles surface with folic acid (FA), as many cancer cells have high folate 
receptor (FR) expression and previous studies have shown considerable particle 
internalization through FR-mediated endocytosis. The nanoparticles were also loaded 
with the poorly water-soluble drug celastrol that has the ability in lower dosages to 
activate the heat shock response and induce the formation of nuclear stress bodies 
(nSBs). The response, in this study the formation of nSBs, was quantified with our 
tailor-made analytical tool that uses BioImageXD; an open source software for 
evaluating the target specificity of these drug-loaded nanoparticles compared to freely 
administered celastrol (II). 
The third specific aim was to create a multidrug-loaded nanoparticle that targets 
cancer cells by utilizing an active targeting ligand combined with a second drug 
loaded inside the particle. The idea is to use an active ligand on the surface of the 
nanoparticle as well as load the particle with an anti-proliferating molecule fingolimod 
(FTY720) that works by inhibiting the phosphorylation of sphingosine and thereby 
blocks the production of the bioactive molecule sphingosine 1-phosphate (S1P), 
which is important for cell growth, survival and migration. The active ligand 
methotrexate (MTX) is a chemotherapy agent that has been used for decades; MTX 
ultimately blocks the synthesis of thymine and purine nucleotides leading to cell 
death. This multidrug-loaded nanoparticle could be used for metastatic cancer 
treatment when conventional cancer treatments have a severe negative effect on the 
patient. As the nanoparticle would first seek the metastatic cell with the targeting 
ligand MTX and then together with the second active molecule FTY720 destroy the 
cancerous cell (III).  
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4. MATERIALS AND METHODS 
This section contains the main aspects of the materials and methods used in this thesis, 
however the details can be found in the original publications and manuscripts (I-III).  
4.1. Synthesis of mesoporous silica nanoparticles 
The mesoporous silica nanoparticle (MSN) core and the polyethyleneimine (PEI) 
coating were synthesized according to our previously published protocols (Nakamura 
et al. 2007, Rosenholm et al. 2006, 2008a&b, 2009, 2010a&b). In our standardized 
procedure, 1.19 g of tetramethoxysilane (TMOS) was mixed with 3-
aminopropyltrimethoxysilane (APS) in an alkaline solution with an H2O: MeOH ratio 
of 60:40, containing the structure-directing agent cetyltrimethyl ammonium chloride 
(CTACl). In order to make the particles inherently fluorescent, 250 µl of a solution 
containing fluorescein isothiocyanate (FITC) in dimethylformamide (DMF; 1 mg/ml) 
was added to the siliane mixture. The resulting alkaline synthesis solution has a molar 
ratio of 0.9 TMOS: 0.1 APS: 1.27 CTACl: 0.26 NaOH: 1439 MeOH: 2560 H2O. The 
solution was kept overnight at room temperature under constant stir and then the 
precipitate was collected by centrifugation, washed with deionized water and ethanol. 
Then the particles were dried in vacuo and the structure-directing agent was removed 
by repeated ultrasonic treatment in acidic ethanol. The polyethyleneimine, PEI, 
branching was grown by adding aziridine under constant stir in a toluene acetic acid 
solution overnight, thereafter the particles were centrifuged, washed and vacuum 
dried and stored for further processing and analysis (I-III).  
4.2. Functionalization and characterization of MSN 
The particle system comprising of a mesoporous silica core and PEI branching layer 
was further functionalized by either sugar motifs, FA or MTX according to procedures 
written in the publication and manuscripts (I-III). The mesoscopic ordering of the 
MSN was detected by powder-XRD using a Kratky compact small-angle system (M. 
Braun, Austria), the particle size and morphology was determined by scanning 
electron microscopy (JSM-6335F, Jeol Ltd., Japan). The hydrodynamic size of the 
particles was determined by dynamic light scattering (ZetaSizer NanoZS, Malvern 
Instruments Ltd., UK) and the mesoporosity by nitrogen sorption measurements 
(ASAP 2010 sorptometer, Micromeritics, USA). Thermogravimetric analysis (TGA, 
STA 449 F1 Jupiter, Netzsch GmbH & Co, Germany) was utilized in order to estimate 
the amount of PEI, sugar motifs, FA or MTX functionalized to the particle. To find 
out the amount of drug loading in the MSNs, samples were first dispersed in ethanol 
for complete drug elution. The drug concentration was determined by UV/vis 
spectroscopy measurements at a wavelength of 425 nm. 
4.3. Image analysis based size distribution of MSNs 
In order to quantify the specific size distribution of the synthetized MSNs, 
transmission electron microscope (TEM; JEM 1400-Plus, JEOL Ltd., Tokyo, Japan) 
operating at 120 kV with a LaB6 filament and a 2 k ×2 k CCD camera was utilized in 
conjunction with ImageJ for post image processing (Souza et al. 2016, Rueden et al. 
2017). First, the scale bar was manually set by the calibration data of each image, and 
then the acquired image was blurred with Gaussian smooth set at 5.00 for minimizing 
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detection of artifacts from being registered as individual particles (Underwood & 
Gorham 2017). Automatic thresholding was then used to divide the image into 
foreground (MSNs) and background, which is based on IsoData algorithm (Ridler & 
Calvard 1978). Then, “Analyze particles” was used to identify and measure the area 
of each individual MSNs (Rueden et al. 2017, Underwood & Gorham 2017). Utilizing 
the formula 𝑑𝑑 = 2 √𝐴𝐴/𝜋𝜋, it was possible to calculate the diameter (d) of each MSN 
from the area (A), producing quantifiable size distributions of the MSNs from the 
TEM images. Objects smaller than 100 nm was considered artifacts or fragments and 
objects bigger than 400 nm were particle aggregates and were therefore excluded from 
the analysis. At least three representative images were acquired from three 
independent experiments (#batches) of synthetized MSNs. The error bars represent 
plus minus the standard deviation of the mean (±SD) of each particle batch and the 
number (n) represent how many individual MSNs were analyzed. Frequency 
distribution was used for representing the size distributions of the total MSNs 
populations from the quantified TEM images. 
4.4. Glucose consumption in normal versus cancerous cells 
The glucose consumption of normal MEF (mouse embryonic fibroblast) versus 
cancerous HeLa (cervical cancer cells) and A549 (lung epithelial carcinomas) cells 
were studied using a Glucose (GO) Assay kit (Sigma-Aldrich, St. Louis, MO, USA). 
First, 105 cells of each cell line were seeded separately in 6 well plates and the cells 
were allowed to adhere overnight. Then the used cell medium was changed with 2 ml 
of unused Dulbecco's Modified Eagle's medium (DMEM) and the cells were allowed 
to consume nutrients for 24 hours. The glucose consumption were then detected at 
540 nm using Hidex Sense Beta Plus microplate reader (Hidex Oy, Turku, Finland). 
The glucose concentration in each sample medium was then calculated using a glucose 
standard curve, and then the obtained glucose amount was subtracted from the 
measured glucose concentration in the unused cell medium containing 45.93 µg/ml 
glucose in order to calculate the glucose consumption in each cell line (I).  
4.5. Specific MSNs uptake in cancer cells 
For the in vitro uptake studies the cancerous target cells that were cultured and used 
were follicular thyroid carcinoma cells (ML-1) and cervical cancer cells (HeLa). The 
non-target cells were mouse embryonic fibroblasts (MEF) cells and normal human 
primary thyroid follicular epithelial cells (Nthy-ori 3-1) or lung epithelial carcinomas 
(A549). The amount of endocytosed particles inside the cell population was analyzed 
by BD FacsCalibur flow cytometer (FL-I; BD Pharmingen, USA) and the data was 
quantified and analyzed using BD CellQuest Pro™ software. For specific particle 
endocytosis studies confocal microscopy Zeiss LSM510 META (Carl Zeiss 
Microscopy GmbH, Jena, Germany) were used to measure FITC intensity inside cells. 
The extracellular fluorescence was quenched with trypan blue and the cell membrane 
was labaled with rhodamine-lectin (Vector Laboratories, Burlingame, California, 
USA). The imgages was taken with 63/100× oil objective using 488 nm excitation and 
500–550 nm emission for detecting the FITC channel, 405 nm excitation with 420–
480 nm emission for detecting the DAPI channel and for detecting the rhodamine-
lectin an excitation of 543 nm with emission filter of 570–600 nm (I-III). 
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4.6. Image quantification of internalized MSNs 
In order to quantify specific particle internalization in the selected cell lines; confocal 
microscopy was employed in combination with image analysis. Cells were incubated 
with 30 µg/ml glucose conjugated inherent FITC fluorescent MSNs for 3 hours. The 
extracellular fluorescent signal was quenched by trypan blue incubation and then the 
cells were fixed, mounted on slides in VECTASHIELD® Mounting Media containing 
4', 6-diamidino-2-phenylindole dihydrochloride (DAPI; Vector Laboratories, 
Burlingame, CA, USA). Particle internalization was detected using a Zeiss LSM510 
META confocal microscope (Carl Zeiss Microscopy GmbH, Jena, Germany) with 
63x oil objective utilizing 405 nm excitation for the DAPI fluorescent stain and 488 
nm excitation for the FITC molecule. The particle internalization was quantified with 
BioImageXD 1.0RC3 software (Kankaanpää et al. 2012). To count the cell numbers 
per image the DAPI channel was used in order to separate the cell nucleus from the 
background. Then the average normalized FITC intensity was measured and divided 
by the total cell number giving a value of FITC intensity per cell (I).  
4.7. Efficacy of drug-loaded MSNs  
In order to measure the drug-loaded nanoparticle efficacy compared to the free drug 
in vitro, DNA fragmentation was measured as a hallmark for apoptotic cells (I-III). 
The method involves detection of the apoptotic cell’s DNA as it starts to fragment and 
these DNA fragments can then bind to propidium iodide (PI). The DNA bound PI 
causes a change in its excitation wavelength that can be detected and quantified by 
flow cytometry (Nicoletti et al. 1991). To verify the toxicity and efficacy of the 
different treatments; WST-1 cell viability assay (Roche Applied Science, Upper 
Bavaria, Germany) and crystal violet was utilized, for counting and monitoring cells 
Bürker chamber was used with Brightfield microscopes (Thomas et al. 2004). 
4.8. Target validation of drug-loaded MSNs  
For drug target validation immunofluorescence analysis was employed. HeLa or A549 
cells were grown on sterile coverslips under either control conditions, heat shocked, 
or treated with celastrol or celastrol-loaded MSNs. Cells were washed, fixed, 
permeabilized and then incubated with blocking solution for 1 hour. Samples were 
kept overnight in cold with rabbit anti-HSF1 antibody (1:400 dilution; Holmberg et 
al. 2000), washed and then incubated with the secondary goat anti-rabbit antibodies 
in a dilution of 1:5000 (Alexa™ 546, Molecular Probes, Eugene, Oregon, USA) in 
room temperature for 1 hour. The samples were mounted and the DNA was stained 
with VECTASHIELD® Mounting Media containing DAPI (Vector Laboratories, 
USA). Images where acquired using a Zeiss LSM510 Meta scanning confocal 
microscope equipped with the SP2 (version 3.2) software and Plan-Apochromat 
63x/1.4 Oil DIC objective, utilizing 405/488 nm and 543/560 nm excitation/emission 
wavelengths. Images was further processed and analyzed using BioImageXD 
software, the DAPI channel was employed for identifying and segmenting the cell 
nucleus. For detecting the nuclear stress bodies the HSF1 channel was segmented 
using dynamic thresholding. Object co-localization was used to analyze the nSBs 
inside the separated cell nucleus, which in turn made it possible to determine the size 
and numbers of nSBs-positive cells within the sample population (II). 
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4.9. Western blot analysis 
Western blot analysis was utilized in order to validate both the downstream effects of 
celastrol as well as to estimate folate receptor (FR) expression levels in the selected 
cell lines (I-III). Cells of interest were grown in control conditions for estimating the 
FR expression or incubated with increasing amounts of celastrol or celastrol-loaded 
MSNs for measuring the heat shock response. Whole cells samples were lysed with 
laemmli buffer containing β-mercaptoethanol and the proteins were denaturated at 
95°C for 10 minutes. Proteins were separated by 10% SDS-PAGE and transferred to 
nitrocellulose membranes. Heat shock protein 70 (Hsp70) were detected with primary 
antibody Hsp70 (StressGen Biotechnologies Inc., Collegeville, PA, USA) at 1:10000 
dilution, folate receptor alpha antibody (FOLR1; Lifespan Biosciences Inc., Seattle, 
WA, USA) was used at 1:1000 dilution and as loading control anti-β-actin antibody 
(Sigma-Aldrich, St. Louis, MO, USA) was used at 1:1000 dilution or anti-Hsc70 
(StressGen Biotechnologies Corp., Victoria, Canada) at 1:10000 dilution. Horseradish 
peroxidase conjugated secondary antibodies (GE healthcare, Buckinghamshire, UK) 
were detected using enhanced chemiluminescence (Amersham Biosciences Corp., 
Piscataway, NJ, USA). Densitometry of the western blot result was performed using 
imageJ and normalized to the loading control (Hartig 2013). 
4.10. Advanced imaging techniques 
To quantify morphological changes in the ML-1 thyroid cancer cells given the 
combination drug treatment of MTX or FTY720. Cells were grown on sterile 6-well 
plate and administered either drug cocktail or drug-loaded MSN using 0.219 µM MTX 
and 4.05 µM FTY720 concentrations. The samples were imaged using the VL21 
instrument (Phasefocus Ltd, Sheffield, UK) with 20x magnification using 20 minutes 
intervals per region of interest (ROI) for a duration of 72 hours. The aim of the 
investigation was to identify apoptotic phenotypes in the ML-1 cells administered 
either free drug cocktail or drug-loaded MSNs using advanced image analysis 
performed by experts from Phasefocus Ltd (III). 
4.11. In vitro invasion assay 
To validate the inhibitory effect of the combinatory drug treatment of MTX and 
FTY720 on cancer cell motility, Boyden chamber invasion experiments were 
conducted with Transwell Permeable Support inserts with 8 µm pore size (Corning 
Inc; Corning, NY, USA; Kramer et al. 2013, Justus et al. 2014). Inserts were coated 
with human collagen IV thereafter cells were added into the upper well that contained 
cell culture medium with 10% FBS, as chemoattractant in the lower well a 20% FBS 
containing medium was used. The concentration of MTX and FTY720 were as 
follows: the low dosage was 0.13 μM MTX and 2.43 μM FTY720, the high dosage 
was 0.438 μM MTX and 8.10 μM FTY720 and the test substances were present in 
both wells. Cells were allowed to invade for 7 hours and then the cells were fixed with 
paraformaldehyde and stained with crystal violet for visualization and counting using 
light microscopy (III).  
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4.12. In vivo drug efficacy studies  
To determine the nanoparticle delivery efficacy in vivo using human-derived 
xenografts in a cost effective way, the chicken chorioallantoic membrane (CAM) 
model was utilized (III; Zeisser-Labouèbe et al. 2004). Fertilized chicken eggs were 
cleaned with 70% ethanol and placed in a 140/200 Rural incubator (FIEM srl, 
Guanzate, Italy) with the narrow apex down for the first three days at 37°C and with 
a relative humidity of around 65%. On embryo development day (EDD) three a few 
mm wide hole were made on the apical side (narrow apex) of the eggshells and the 
puncture was sealed with adhesive tape. Then the eggs were left in the incubator at 
static mode for five more days with the narrow apex upwards. ML-1 cells were grown 
in complete Dulbecco's modified eagle's medium (DMEM), harvested and re-
suspended at an density of 1 x 106 cells per 10 µl in serum-free media and mixed with 
equal amount of Matrigel (Growth Factor Reduced Basement Membrane Matrix; 
Corning) at EDD 8. In parallel, the hole in the eggshells was enlarged with pliers to 
2-3 cm and 20 µl of cell suspension was inoculated in a plastic O-rings near major 
blood vessels at the CAM. In order to protect the embryo, a plastic film was used to 
seal the opening of the eggshell and the eggs were returned to the incubator and kept 
at static mode until next step of procedure. At EDD 9 the MTX and FTY720 drug 
cocktail and multidrug-loaded MSNs were suspended in physiological HEPES buffer 
at pH 7.2 to concentrations ranging from 1-10 μg of FTY720 / 30 μl (33.3-333.3 
μg/ml) and 0.1-1 μg MTX / 30 μl (3.3-33.3 μg/ml) and the treatment volume was 30 
μl per egg. The forming tumors were imaged on each day that follows until EDD 12, 
at which point the solid tumors are excised and weighed as an end point measurement 
in order to validate the tumor mass. Then the tumors were fixed in paraformaldehyde 
and stored in paraffin embedded blocks that were cut for further histological 
preparations. 
4.13. Immunohistochemistry of tumor samples 
The paraformaldehyde fixed and paraffin embedded tumors were cut into 4 µm 
sections and immunohistochemically stained with antibodies and reagents listed in the 
article (III). In brief, antigens were retrieved using high-temperature in Tris-EDTA 
buffer (pH 9), washed in TBS with 0.1% Tween20 (TBST; Sigma-Aldrich, Saint 
Louis, MO), blocked in 3% BSA (Sigma-Aldrich) in TBST for 1 hour at room 
temperature then incubated overnight with the primary antibody. On the next day, 
slides were washed 3x with TBST, incubated with secondary antibody for 30 min, 
washed three times in TBST and visualized using Liquid DAB+ Substrate Chromogen 
System (Dako, Glostrup, Denmark). Slides were scanned by Pannoramic 250 Slide 
Scanner (3DHISTECH Ltd., Budapest, Hungary). 
4.14. Statistical analysis  
Statistical significance between samples was determined by One-way analysis of 
variance with Bonferroni post hoc test or Tukey's multiple comparisons test, using 
GraphPad Prism® 5.0 or 6.0 (San Diego, California, USA). If the p-value was less 
than 0.05 the data was considered significantly different. The error bars represent plus 
minus the standard error of the mean (±SEM) or standard deviation (±SD) and the 
number (n) of samples is indicated in the figure legends (I-III).  
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5. RESULTS AND DISCUSSION 
5.1. Mesoporous silica nanoparticles as targeting systems 
This thesis contains proof-of-concept on how to target specific cell populations by 
functionalized drug-loaded nanoparticles. Enabling significantly less off-target effects 
when administering different compounds such as celastrol, MTX and FTY720 as the 
drug is accumulated and retained in the cells of interest (I-III). Cancer cells were 
chosen as model system because of cancer being one of the main cause of death in the 
western world, and many of the cytostatic drugs still in use were developed decades 
ago with substantial side effects on the patients (Allan & Travis 2005, Wicki et al. 
2015). Consequently, there is a high demand of developing new forms of cancer 
treatment with minimal off-target effects, and nanoparticles have shown considerable 
potential as targeted drug delivery systems (Meijerman et al. 2008, Vivero-Escoto et 
al. 2010). Nanoparticle-based drug delivery systems can easily be adapted to specific 
internalization pathways for different organs and disease conditions by changing the 
targeting ligand and surface functionalization (Bae & Park 2011). For instance, cancer 
cells growth advantages is also their biggest disadvantage, as most cancer cells have 
an increased metabolism and cell division that can be utilized as targeting strategies 
(Malhotra & Perry 2003, Zhang & Yang 2013). These cancer specific traits are the 
basis of the studied targeting pathways; as either Gluc, FA or MTX conjugated 
nanoparticles were synthetized in this thesis. The second step in designing the delivery 
system is to choose what kind of materials should be used for the particle core, so that 
the drug of interest can be loaded to the carrier with desired release kinetics without 
premature release. In addition, the size of the particles needs to be considered, as large 
particles tend to aggregate in biological systems and tiny nanoparticles can 
spontaneously penetrate the cell membrane leading towards unspecific internalization 
in healthy cells (Verma & Stellacci 2010, Albanese et al. 2012). The surface 
functionalization influence also particle toxicity and particle internalization as well as 
drug release kinetics (Yue et al. 2011, Baltazar et al. 2012). Due to these demanding 
requirements, MSNs of modular design in the size range of 250-300 nm were 
synthetized and evaluated for the use as targeting delivery system for cancer cells.  
5.2. Characterization of the synthetized MSNs 
The MSNs were synthetized according to the procedure described in the materials 
methods section, based on similar protocols used in previous studies (Rosenholm et 
al. 2006, 2008a&b, 2009). Four different batches of synthetized MSNs were 
characterized in this thesis by different methods in order to compare possible 
variations of these particles (I-III). Electron microscopy was utilized in order to 
confirm the average particle size, monodispersity, morphology and the mesoscopic 
ordering (Figure 13). The transmission electron microscopy (TEM) reveals that these 
MSNs have similar porous structure with radially aligned mesopores, and that the 
average particle size based on the image analysis was around 208 d.nm (Figure 13). 
The particle size distribution shows that from the 118 analyzed particles around 100 
particles were in the size range of 160 – 280 d.nm, verifying a homogenous particle 
population (Figure 13f). From the scanning electron microscopy (SEM), it was 
possible to confirm that the average diameter of the particles was indeed around 200-
300 d.nm and that the whole particle population had similar morphology (Figure 13d).  
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Figure 13. Characterization and size estimation of MSNs. a) TEM image of synthetized MSNs 
from batch #1, b) TEM image of synthetized MSNs from batch #2, c) TEM image of synthetized 
MSNs from batch #3, d) SEM image of synthetized MSNs from batch #4, e) image quantification 
of size difference (d.nm) between batches, f) size distribution (d.nm) in the whole MSN population. 
Total amount of MSN quantified (n=118), error bars represents mean ± SD, * P ≤ 0.05, **** P ≤ 
0.0001. Size distribution of objects in diameter (d.nm) and scale bar in images a-c are 100 nm. 
Intriguingly, some particle size variations were detected between the synthesis batches 
(Figure 13a-e). However, when comparing the average size of each batch to the size 
distribution of the whole particle population, the variation is within the highly 
probable (~85 %) average size range of 180 – 280 d.nm (Figure 13). It is know that 
differences in temperature, pH, relative humidity, type of surfactant used and 
surfactant concentration could affect the shape and size of the synthesized particles 
(Wan & Zhao 2007, Desai 2012, Ducheyne et al. 2015, Donald et al. 2016, Baer et 
al. 2018). That could at least partly explain the minor variations in particle size 
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between batches as the particles were synthetized at different time points and in 
different facilities that could influence external factors. The zeta potential and 
hydrodynamic size of the synthetized particles were measured with dynamic light 
scattering in HEPES buffer at physiological pH 7.2. The “bare” non-functionalized 
particle shoved lower zeta potential than the PEI branched particles as well as ligand 
conjugated particles, indicating successful functionalization (Table 2). The 
hydrodynamic size confirmed full redispersibility of all 4 synthetized particle batches 
as well as an indication that the first batch of particles had the smallest diameter, which 
corresponds to the TEM images as well as the quantification (Table 2 & Figure 13). 
To determine surface area, pore size and pore volume, N2-sorption measurements was 
performed and the arrangement and size of the mesopores was detected with small 
angle X-ray (SAXRD) and the pore width of all analyzed particles were in the range 
of 3 – 3.5 nm in size (Table 2). In addition, thermogravimetric analysis (TGA) was 
used to determine the organic content of the PEI branched particles and the amount of 
functionalized targeting ligand on the particles surface used in this thesis (Rosenholm 
et al. 2009). Based on the TGA analysis, batch number 4 had less PEI branching than 
batch #1, whereas batch #2 and #3 were quite similar in terms of PEI content. 
Differences in particle functionalization/charge influence internalization as generally 
positively charged particles tend to be taken up in larger quantities, however the ligand 
functionalization influences the overall net charge that was similar in all particles. 
Table 2. Physiochemical characterization of synthetized MSNs (I-III). 
Synthesized Particles (# batch number) #1 #2 #3 #4 
Targeting ligand (abbreviation) n/a FAaq MTXaq GAorg 
Hydrodynamic size of MSN (d.nm) 243 n/a n/a 341 
Hydrodynamic size of PEI-MSN (d.nm) 384 396 488 490 
Hydrodynamic size of ligand-PEI-MSN (d.nm) n/a 451 373 447 
Zeta potential of MSN (mV) -26.3 -2.4 n/a -5.5 
Zeta potential of PEI-MSN (mV) 28.3 41.2 57.0 50.3 
Zeta potential of ligand-PEI-MSN (mV) n/a 53.1 54.0 52.4 
Fluorescence intensity of MSN (520 nm) 956 n/a n/a 840 
Fluorescence intensity of PEI-MSN (520 nm) 432 n/a 292 439 
Fluorescence intensity of ligand-PEI-MSN (520 
nm) n/a n/a 168 385 
Organic content of PEI-MSN (weight %) 33 34 34 24 
Targeting ligand content (weight %) n/a ~1 2.10 0.95 
Pore volume of MSN (cc/g) 1.856 n/a 0.754 0.833 
Pore width of MSN (nm) 4.093 n/a 3.537 3.537 
Pore volume of PEI-MSN (cc/g) 0.821 n/a 0.305 0.281 
Pore width of PEI-MSN (nm) 3.537 n/a 3.179 3.06 
Drug of interest n/a Celastrol FTY720 Celastrol 
Drug loading degree (%) n/a 4.10 27.86 2.57 
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5.3. Functionalization influence drug loading and release kinetics 
In this thesis, different drug molecules were loaded or conjugated to ligand 
functionalized MSNs in order to evaluate the drug delivery potential of these carrier 
systems (I-III). The loading degree inside the particle with the hydrophobic drug 
celastrol was between 2.57 – 4.1 % of weight depending on batch variations, whereas 
the drug FTY720 could be loaded to 27.8 – 33.2 weight percentage depending on the 
functionalization of the particle (Table 2). However, as celastrol was the focus of this 
thesis, the drug release kinetics were further studied utilizing UV/vis spectroscopy. 
The in vitro release kinetics of both free celastrol and celastrol-loaded MSNs was 
done in HEPES buffer at 7.2 pH for simulating physiological conditions. Already after 
48 hours, the free celastrol had dissolved to a degree of 50 % in the aqueous solution, 
which is not desirable for intracellular drug delivery as the drug should be released at 
the target site and not prematurely (Figure 14). The non-functionalized particles 
showed also rapid release kinetics as after 6 hours around 20 % was released from the 
carrier, whereafter the release curve stagnated (Figure 14). The rapid release could be 
explained by excessive drug molecules on the surface of the particles that are almost 
immediately dissolved in the solution. The functionalized particles does not exhibit 
the same rapid release kinetics, which demonstrates that that PEI branching does 
indeed function as an “molecular gate” preventing premature release of the drug 
preventing the possible drug interaction with healthy cells (Zhou et al. 2018). Drug 
release kinetics of functionalized MSNs depends also on drug solubility, 
environmental conditions and the degradation properties of the silica material used in 
the particle (von Haartman et al. 2016, Hao et al. 2012). The slow release kinetic is 
beneficial in intracellular drug delivery as it can take several hours for the particle to 
reach target tissues and can remain there for days (Yu et al. 2016, Park & Park 2016). 
 
Figure 14. Hydrophobic drug release kinetics. Release/dissolution kinetics of free celastrol, 
celastrol-loaded control MSNs, celastrol-loaded MSN-PEI and celastrol-loaded MSN-PEI-GAorg 
in HEPES buffer (pH 7.2) for a duration of 48 hours (adapted from I).  
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5.4. Functionalization affects particle toxicity 
In this part, the in vitro toxicity of different surface functionalization was investigated 
in order to evaluate the potential application of these MSNs as carrier systems. The 
toxicity results from lower particle concentrations (up to 10 ug/ml) shows no 
significant difference compared to the control (I-III). Higher particle concentrations 
(30 µg/ml) for 24 hours was studied in HeLa cells using propidium iodide (PI) staining 
and the apoptotic population was measured by flow cytometry. The results shows that 
non-functionalized particles are indeed more toxic to cells compared to functionalized 
particles (Figure 15). The slightly more toxic effect could be a result of non-
functionalized particle tendency to aggregate in aqueous solution, which inside the 
cell would results in DNA damage detected by flow cytometry (Nicoletti et al. 1991, 
Shang et al. 2014). Other studies have shown that non-functionalized particles are 
more toxic to cells than functionalized particles (Chung et al. 2007, Lee et al. 2010b). 
On the other hand, positively charged nanoparticles are considered more toxic to cells 
as they tend to interact with negatively charged proteins and DNA (Fröhlich 2012). 
The PEI itself have shown to be toxic when freely administered to cells, however no 
significant cytotoxicity have been reported when using PEI functionalized MSNs in 
previous studies (Desai et al. 2014, Kettiger et al. 2015). Indicating that the possible 
PEI toxicity can be suppressed when made in a larger construct such as a PEI branched 
MSN (Figure 15). The possible toxicity of functionalized nanoparticles should 
therefore be evaluated on a case-by-case basis, as looking separately on each 
component can give a misleading interpretation.  
 
Figure 15. Toxic effect of different functionalized MSNs at 30 µg/ml measured after 24 hours 
incubation with HeLa cells using PI staining. Non-functionalized particles shows significant 
toxicity compared to vehicle control (DMSO 1.2% w/v) and functionalized particles. Error bars 
represent ± SEM (n≥3), *** P ≤ 0.001 (adapted from supp. file I). 
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5.5. Glucose consumption as targeting strategy in cancer cells 
One of the most important aspects in targeted drug delivery is figuring out a way of 
achieving high drug accumulation in target tissue with minimal off-target effects. This 
is possible when utilizing differences in the cells of interest as a “Trojan horse” for 
targeting specific cell populations. One of the hallmarks of cancer is their tendency 
for accelerated cell growth followed by an increased metabolic activity. Cancer cells 
have an altered metabolism, whereas normal cells generate adenosine triphosphate 
(ATP) by aerobic respiration by complete oxidation of glucose molecules in the 
mitochondria. Cancer cells on the other hand generates ATP through glycolysis that 
consumes significantly more sugars per generated ATP molecule, producing lactates 
as a by product (Zhang & Yang 2013, Liberti & Locasale 2016). However, glycolysis 
has its benefits, as it is 10-100 times faster than aerobic respiration and hypothetically 
this increased glucose consumption gives cancer cells an additional carbon source for 
anabolic processes needed for the rapid cell proliferation (Liberti & Locasale 2016). 
Therefore, Glucose assay kit was utilized in order to verify these metabolic differences 
in cancerous HeLa and A549 cells compared to normal MEF. The assay show that 
both HeLa and A549 cancer cells consume significantly more glucose than normal 
MEF cells (Figure 16). De facto, HeLa cells consumes over twice as much glucose 
after 24 hours than MEF cells. This elevated cancer cell metabolism was utilized as a 
targeting strategy for drug delivery in this thesis by conjugating sugar moieties on the 
surface of these MSNs (I). 
 
Figure 16. Glucose consumption in MEF, A549 and HeLa cells after 24 hours. The cancer cells 
have significantly higher glucose consumption than MEF cells seen after 24 hours incubation in 
complete DMEM. Error bars represent ± SEM (n=3), ** P ≤ 0.01, *** P ≤ 0.001 (adapted from 
supp. file I). 
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5.6. Functionalization affects particle internalization 
In order to investigate the effect of particle functionalization and targeting ligand 
conjugation on cellular internalization, both flow cytometry and confocal microscopy 
was utilized. First two different cancer cells (HeLa and A549) with high metabolism 
compered to normal MEF cells was utilized to provide proof of concept that cancer 
specific internalization can be achieved with sugar moieties on the particle surface 
(Figure 17&18). Intriguingly, when conjugating sugar molecules directly on the 
“bare” particle surface there were no significant increase in particle uptake in either 
cancer cell lines. Only when conjugating the targeting ligand to PEI branched particles 
an increased internalization was observed. We could speculate that a certain net 
positive charge is necessary for particle internalization as the PEI functionalized 
particles themselves had an increased internalization compared to bare particles, and 
that the PEI branching is essential for the further increased efficacy of the targeting 
ligand (Figure 18 & Table 2). However, it was not possible to distinguish which sugar 
targeting ligand was the most efficient in the terms of uptake percentages in the cancer 
cells. Therefore, normalized mean fluorescence intensity was calculated from 10 000 
cells against each functionalized particle fluorescence which provided the information 
that the MSN-PEI-GAorg had the highest uptake in cancer cells (Figure 18b&d). The 
functionalized particle uptake in normal MEF cells was around four times lower 
compared to that of the cancer cells demonstrating selective internalization (Figure 
17). In order to confirm that the particles were taken up by the cancer cells and not 
aggregated on the cell membrane, confocal microscopy was employed. The cell 
nucleus was stained with DAPI, the cell membrane stained with rhodamine-lectin and 
the FITC fluorescent particles visualized inside the cell; thus confirming particle 
internalization (I). Furthermore, confocal images of HeLa cells administered with the 
different targeting ligand quantified using BioImageXD showed significantly higher 
internalization of the MSN-PEI-GAorg validating the selected targeting motif (I). 
 
Figure 17. Flow cytometry quantification of MSNs internalization in MEF cells after 3 hours 
incubation. a) Mean % of FITC positive cells using 5 µg/ml of nanoparticles or control. b) 
Normalized mean fluorescence intensity resulting from particle uptake in MEF cells. Error bars 
represent ± SEM (n≥4), *** P ≤ 0.001 (I). 
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Figure 18. Flow cytometry quantification of the cellular internalization of MSNs in two 
different cancer cells after 3 hours incubation. a) Mean % of FITC positive HeLa cells using 5 
µg/ml of nanoparticles or control. b) Normalized mean fluorescence intensity resulting from 
particle uptake in HeLa cells. c) Mean % of FITC positive A549 cells using 5 µg/ml of 
nanoparticles. d) Normalized mean fluorescence intensity resulting from particle uptake in A549 
cells. Error bars represent ± SEM (n≥4), ** P ≤ 0.01, *** P ≤ 0.001 (I). 
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5.7. Folic acid targeting towards folate receptor expressing cells 
Another cancer specific trait that can be utilized as targeting strategy is by conjugating 
folic acid (FA) on the particle surface, as many cancer cell have a tendency of 
overexpressing folate receptors (FR) on the cell membrane, consequently allowing for 
receptor-mediated endocytosis (Leamon & Low 2001, Leamon & Reddy 2004, 
Rosenholm et al. 2009). In this part of the study, HeLa cells was chosen as the cancer 
cell model as they express folate receptors in high quantities, whereas A549 cells were 
selected in this case as the “non-cancerous” cell model as they have negligible 
amounts of FR at their cell membrane (II; Parker et al. 2012). The flow cytometry 
results shows that FA-PEI-MSN are internalized in significantly higher amounts in 
HeLa cells than A549 cells, as the uptake difference is ten-fold higher in target cells 
compared to off-target cells (Figure 19a). To validate successful particle endocytosis, 
confocal microscopy was utilized and the fluorescent particles are seen as green dots 
inside the cell membrane visualized in magenta (Figure 19b). However, some healthy 
cells do express FR and could thus internalize FA conjugated particles giving rise to 
potential off-target effects (Parker et al. 2005, O'Shannessy et al. 20015). Therefore, 
we studied also cells that originates from the thyroid gland that express variable 
amount of FR for evaluating some of the FA targeting pitfalls (Weber et al. 2013, 
Shen et al. 2015). The cells used were thyroid follicular cancer cells (ML-1) and 
normal thyroid cells (Nthy-ori 3-1) and HeLa cells as the FR positive cell line which 
is known to internalize FA conjugated MSNs (III).  
The quantification of the western blot results shows that both thyroid cell lines do 
express FR (Figure 20). However, there are significantly lower expression levels in 
the normal thyroid cells that functions as the basis for this targeted drug delivery 
strategy towards thyroid cancer cells (Figure 20b). The flow cytometry result shows 
that the FA-PEI-MSN are internalized in higher amounts in the cancerous thyroid cells 
(ML-1) compared to the normal thyroid cell (Nthy-ori 3-1) indicating that receptor 
expression levels are not the only affecting factor in particle internalization (Figure 
20). The confocal images verifies that these FA conjugated nanoparticles are indeed 
internalized by cancerous thyroid cells and that normal thyroid cells only internalize 
low amounts of particles (Figure 20d&e). Receptor turnover is known to affect 
antibody internalization kinetics and, therefore, the FR turnover rate could potentially 
influence particle internalization (Paulos et al. 2004). However, such aspect would 
need to be further studied to know the effect of receptor turnover on particle 
internalization. Furthermore, mathematical models can be used for estimating the 
optimal nanoparticle size and the density of the targeting ligand on the surface on the 
particle for effective binding to cell specific receptor clustering on the cell membrane 
(Gonzalez-Rodriguez & Barakat 2015). Therefore, it is possible that the observed 
higher internalization in the thyroid cancer cells is due to rapid receptor turnover 
and/or matching particle targeting ligand/receptor clustering on the cancerous cells 
compared to the normal cells that also express FR at their cell membrane (III). 
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Figure 19. Cellular uptake of FA-PEI-MSNs in cells after 3 hours incubation. a) Flow 
cytometry quantification showing mean % of FITC positive HeLa and A549 cells using 1 µg/ml of 
nanoparticles or untreated cells (control), error bars represent ± SEM (n≥4), **** P ≤ 0.0001. b) 
Confocal microscopy images of FA-PEI-MSN endocytosis in HeLa cells at 10 µg/ml 
concentrations, using DAPI nuclear staining (blue), rhodamine-lectin plasma membrane staining 
(magenta) and particles conjugated with FITC (green), scale bar 10 µm (II).  
Even though there is particle internalization in normal thyroid cells; this would not 
pose any major concern in the case of thyroid cancer, as surgical removal of the 
thyroid is the mostly used treatment method (Clark et al. 1988). The real off-target 
risk is the other tissues that express FR, which are the proximal tubules of the kidney, 
the choroid plexus, intestinal brush-border membranes, pneumocytes in the lung and 
placental tissue (Parker et al. 2012). However, in the case of intravenous injection of 
nanoparticles with FA targeting ligand to the blood stream, the possible off-target 
effects would be minor. This is because the theoretical internalization at the intestine 
would only be feasible if the carrier would be ingested orally, and entering the brain 
would require penetrating the blood brain barrier, which is highly unlikely for 
macromolecules or, in this case nanoparticles with a size over 200 nm (Ballabh et al. 
2004). Particle accumulation in the lungs is also unlikely as folate-based 
radiodiagnostic agents when administered intravenously to patients do not accumulate 
in the lungs despite of their high FR expression. One possible explanation for this 
phenomenon could be that the apically oriented FRs in the lung epithelium are not in 
contact with the circulating blood and therefore, the injected folate-derived imaging 
agents cannot accumulate in the lung tissue (Parker et al. 2012). The FR expression 
in placenta during pregnancy could pose a potential threat for the embryo when 
administering folate-targeting nanomedicines. However, conventional chemotherapy 
for pregnant women poses already a threat for the embryo and should therefore only 
be given under special circumstances e.g. under later stages of the pregnancy in order 
to reduce the risk of birth defects (Esposito et al. 2016). Therefore, the most likely 
affected organ would be the kidneys, as FR are highly expressed in the proximal 
tubule where its function is to filter small molecules and proteins from the urine 
(Eshbach & Weisz 2016). Fortunately, our nanocarrier system is designed to be 
relatively large and cannot directly pass the glomerulus and therefore, our particle 
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would remain in the blood circulation and would not enter the proximal tubule where 
potential off-target internalization could occur (He et al. 2011, Liu et al. 2013). 
Summa summarum, developing targeting strategies is a complicated task, where the 
characters of the cell of interest needs to be carefully considered in order to create an 
carrier system that matches the criterion of the living organism for optimal 
internalization and drug retention in target tissues.  
 
Figure 20. In vitro uptake efficasy of folic acid conjugated nanoparticles. a) Flow cytometry 
quantification of cellular uptake of FA-PEI-MSNs shown as % FITC positive cells using 1.5 µg/ml 
of nanoparticles in ML-1 cell compared to Nthy-ori 3-1 cells after 4 hours incubation. b) 
Quantification of FRα protein levels in Nthy-ori 3-1 cells and ML-1 cells. c) Folate receptor protein 
expression in Nthy-ori 3-1 cells (1,3,5), ML-1 cells (2,4,6), and HeLa cells (7) as a FRα positive 
control. Confocal microscopy images of MSN-PEI-FR endocytosis in d) ML-1 cells and e) Nthy-
ori 3-1 at 1.5 µg/ml for 4 hours with scale bar of 10 µm. Error bars represent ± SEM (n≥3), * P ≤ 
0.05, *** P ≤ 0.001 (III). 
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5.8. Particle toxicity depends also on cell type 
Particle toxicity is not only dose, material or functionalization dependent; the toxic 
effect varies also with what cell type is being affected and the amount of particles are 
internalized in that specific tissue (I-III). In order to study the potential unwanted/off-
target effect of these PEI functionalized MSNs in normal versus malignant cells; we 
utilized follicular thyroid carcinoma cells (ML-1) and normal human primary thyroid 
follicular epithelial cells (Nthy-ori 3-1) at concentrations up to 60 µg/ml for 72 hours 
(III). In order to detect more subtle changes in the cellular homeostasis resulting from 
administering these non-drug loaded MSNs, we utilized a metabolic viability assay 
(WST-1; Guertler et al. 2011). It is known that silica materials are generally 
considered safe and significant toxicity of MSNs are only detectable when using non-
functionalized particles in high doses, where the toxicity is most likely caused by 
particle aggregation and not the particle composition (Srivastava et al. 2015, Paatero 
et al. 2017). The viability assay shows that normal thyroid cells are more susceptible 
compared their cancerous counterparts to possible effects of MSNs when high enough 
doses are given (60 µg/ml) for prolonged durations (72 hours; Figure 21). There is 
less variation in the cell viability when administering different concentrations of 
MSNs to ML-1 cells compared to the Nthy-ori 3-1 cells. The normal thyroid cells 
shows variation in viability depending on the amount of particles administered; 6 – 
24 µg/ml gives higher viability compared to the negative control (no treatment) 
whereas 60 µg/ml decreases viability. When comparing the two cell lines viability 
using two-way ANOVA the results shows that there is a significant difference when 
administering these MSNs for prolonged exposures. A moderate amount of particles 
(6 – 24 µg/ml) gives an metabolic advantage to the normal thyroid cells and high 
concentrations (60 µg/ml) gives an negative effect on the normal cells, whereas the 
cancerous cells only shows minor variation in different concentrations (Figure 21). 
The efficacy of different drug-loaded nanoparticles is a well-studied subject; however, 
the metabolic effect of non-drug loaded MSNs has on cells is a less studied matter. 
One study done by Huang and collages showed that increasing amounts of MSN with 
prolonged exposure actually increases cell viability detected by MTT assay in human 
malignant melanoma (A375) cells. The promoted proliferation could be through an 
oxidative mechanism where the increasing amount of particles increases oxidation 
leading towards the inhibition of NF-kB activation and upregulation of Bcl-2 
expression (Huang et al. 2010). The Bcl-2 protein represent anti-apoptotic proteins 
that shifts the cellular homeostasis toward survival, which could be the explanation of 
the increased proliferation detected in these A375 cancerous cells (Elmore 2007, 
Huang et al. 2010, Hongmei 2012). However, our viability data shows that that normal 
cells on the other hand has a limit on the proliferation effect of PEI-MSNs as high 
concentration lowers the metabolic rate of Nthy-ori 3-1 cells (Figure 21). Therefore, 
it is hard to predict the effect different nanoparticles has on each specific cell line as 
the metabolic state and protein expression pattern of different tissues varies. Not to 
mention cancerous cells versus normal cells can have quite different phenotype and 
genotype that can greatly affect the outcome of different treatment forms (Lee et al. 
2010a, Ozaki & Nakagawara 2011, Hilgendorf et al. 2013, Paatero et al. 2017).  
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Furthermore, the negative effect detected in these healthy cells is quite artificial, as 
most of the intravenously administered particles in potential patients would spread out 
to the whole body, and only a few percent of the particles tend to accumulate at target 
sites and even less to possible healthy cells (Bae & Park 2011). Especially when using 
active targeting as most healthy cells do not overexpress FR or glucose transporters 
(GLUT) and would thus not internalize FA/Gluc conjugated MSNs and, therefore, the 
negative effect at healthy tissue of the carrier itself would remain minute (Parker et 
al. 2005, Liberti & Locasale 2016). Furthermore, these in vitro studies are made in a 
closed artificial platform where particle accumulation would be far higher than in the 
in vivo situation where these particles would partially be degraded and cleared from 
circulation by the liver and kidneys and thus, particle concentration at possible off-
target sites woulde be considerably lower in man (Owens & Peppas 2006, Park & Park 
2016, Del Agua et al. 2018). Taken together, it is important to study particle toxicity 
first in vitro, then equally important is to study the possible off-target effect in vivo 
for understanding such complex interaction between the carrier material and the living 
organism for going forward in the product development and twoards clinical trials. 
  
 
 
Figure 21. The PEI functionalized MSNs have variable effect on cells metabolic activity after 
72 hours incubation. The cancerous ML-1 cells show minor differences in cell viability when 
administering different concentration of MSNs. The normal thyroid cells (Nthy-ori 3-1) shows high 
variations in cell viability depending on the administered concentration of particles. All data sets 
were compared with a negative control (NC) without treatment and a positive control (PC) 
containing caliculin A as well as solvent controls (DMSO). Statistical difference were calculated 
using Two-way ANOVA with Tukey's multiple comparisons test. Error bars represent ± SEM 
(n=3), *** P ≤ 0.001, **** P ≤ 0.0001 (supp. file III). 
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5.9. Particle internalization are time and concentration dependent 
Particle internalization could be considered a chemical reaction where increasing the 
amount of the starting substance X (particles) pushes the reaction towards becoming 
the final substance Y (internalized; Kayala et al. 2011). Then the cell type and thus 
the amount of receptors available at the surface that can facilitate the reaction 
influence greatly the time needed for the reaction to take place, a little like an thermal 
reaction where high heat (high receptor expression) increases the reaction time 
whereas lower temperatures (low receptor expression) are sub-optimal and therefore 
the limiting factor. However, by giving prolonged time points it is possible to achieve 
reactions that are not favorable; and this is holds true also in particle internalization 
kinetics. In order to exemplify at least some of these assumptions, we studied the 
internalization kinetics at different particle concentrations as well as different time 
points. Utilizing cervical cancer cells (HeLa) and cancerous thyroid cells (ML-1) that 
are known to internalize particles as well as normal thyroid cells (Nthy-ori 3-1) that 
internalize particles in lower amounts, for simulating a more realistic scenario where 
some of the healthy cells in the body do express FRs for evaluating possible off-target 
internalization (Figure 22).  
 
 
  
Figure 22. Flow cytometry quantification of concentration dependent internalization kinetics 
of folate acid conjugated MSNs. Mean % of FITC positive cell population in ML-1, Nthy-ori 3-1 
and HeLa cells using 0 - 30 µg/ml of folate conjugated nanoparticles after 4 hours incubation. Error 
bars represent the standard deviation ± SD of the mean (n=4; unpublished).  
The flow cytometry results shows that ML-1 cells has the highest uptake of these three 
cellines when administering FA conjugated particles, as over 90% of the ML-1 cell 
population are FITC positive already at low concentrations (1.5 µg/ml). HeLa cells 
shows a steady increase of internalized particles when the particle amount increases, 
possible indicating that HeLa cells that has a high expression of FR can handle the 
high particle load and still efficiently internalize the increased amount of particles 
(Figure 22). The interesting observation here is that HeLa cells express higher amount 
of FR compared to ML-1 cells however, the ML-1 cells yields higher FITC positive 
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population (Figure 22&20). The normal thyroid cells that have low expression of FR 
do internalize these particles in a less effective manner compared to these two 
cancerous cell lines that overexpresses the receptor. Even after administering 30 
µg/ml of particles, the FITC positive population in the normal thyroid cells is still 
under 70% from the whole population, indicating that the lower amount of receptors 
are not able to internalize the increasing amount of particles which the cancerous cells 
are capable of internalizing (Figure 22&20).  
Furthermore, by comparing internalization of passive targeting versus active targeting 
in a time dependent function by using high amount of administered particles, it is 
possible to study some of the benefits of active targeting utilizing MSNs (unpublished 
data). By using high amounts of particles (30 µg/ml) it was possible to minimize the 
uptake effects caused by the amount of particles available so that the particles 
themselves would not be the limiting factor in this reaction. As expected, the time 
dependent experiment shows that by prolonging the incubation time it was possible 
the increase the internalized particles seen as an increasing FITC positive population 
in both passive and active targeting. However, by using active targeting it is possible 
to achieve a higher initial uptake in target cells compered to passive targeting that 
would be beneficial in personalized drug treatment, where fast uptake of drugs in 
target tissues would minimize side effects in off-target tissues (data not shown). Taken 
together, it is clear that functionalized particle uptake is not simply dependent on the 
expression levels of the target receptor or that the cell of interest will either internalize 
the particle or not. Considering particle uptake as a living reaction would be a more 
accurate presumption, where the amount of particles and time given for the reaction 
together with the amount of available receptors and receptor turnover at the cell 
membrane all influences the output (Oh & Park 2014). Therefore, doing uptake 
kinetics with different particle concentrations and different time points using both the 
target cells and off-target cells would give more realistic information regarding 
particle internalization kinetics of a living multicellular organism. However, such 
detailed in vivo studies are not always plausible and therefore low concentrations of 
particles with a few hours of incubation time would be a good starting point for the in 
vitro uptake studies. 
5.10. Active targeting with MSNs increase drug efficacy 
In order to confirm improved efficacy of the hydrophobic drug celastrol when loaded 
into MSNs compared to freely administered drug, the apoptotic effect was validated 
in HeLa cells by propidium iodide staining. The nuclear propidium iodide (PI) 
staining was selected as viability method that relies on PI binding to fragmented DNA 
as a marker for cell death (Nicoletti et al. 1991). Based on celastrol’s ability to 
destabilize the microtubules that disrupts fast dividing cancer cells, thereby inducing 
DNA breaks and ultimately cell death (Jo et al. 2010). The flow cytometry results 
shows that an apoptotic effect can be detected already after 24 hours when freely 
administering celastrol of concentrations around 3-7 µM (Figure 23a). This apoptotic 
effect is probably due to the mitotic rate of HeLa cells that is around 8-12 hours, 
therefore 24 hours incubation is sufficient for celastrol to induce mitotic catastrophe 
leading towards apoptosis (Piras & Piras 1975, Nagase et al. 2003). Longer durations 
and higher dosages did not increase the apoptotic effect, which could be explained by 
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the fact that prolonged exposure and high concentrations of toxins leads generally to 
necrosis and fragmentation of cells that are not easily detectable by apoptotic assays 
such as PI staining (Kroemer et al. 2009, Orrenius et al. 2011). Therefore, the optimal 
time point and dosage for inducing apoptosis in HeLa cells was around 5.3 µM of 
celastrol when incubated for 24 hours. However, the maximal effect in terms of 
apoptosis by freely administered celastrol was quite low, around 5-10 percentage, 
which could partially be explained by to poor solubility of the drug in aqueous 
solution. As there were some variations in the apoptotic effect of free celastrol on 
cancer cells when comparing different experimental repetitions (Figure 23a&b). HeLa 
cells were then incubated with celastrol-loaded MSNs with corresponding 
concentration (5.3 µM) in order to assess the potential gained anti-cancerous efficacy 
in terms of apoptosis utilizing sugar conjugated nanocarrier systems. All 
functionalized particles showed significant enhancement of drug efficacy compared 
to freely administered drug. Intriguingly, the GAaq-PEI-MSN showed lower efficacy 
compared to the other particles studied (Figure 23b). This particular functionalization 
was carried out in aqueous conditions and exposure to water is known to affect the 
silica matrix i.e. also pore structure, which may in turn influence drug loading and 
drug release (Desai et al. 2014).  
 
To confirm the potential beneficial effects of celastrol and celastrol-loaded MSNs, the 
cytoprotective effect was studied in FR positive HeLa cells and FR negative A549 
cells by measuring the heat shock response using western blot analysis. The 
incubation time was set at 6 hours in order to avoid the toxic effect of celastrol on fast 
dividing cells; however, giving enough time for detecting changes in expression levels 
of one of the most important molecular chaperone called Hsp70 (Salminen et al. 
2010). The western blot analysis shows that HeLa cells are more susceptible to the 
beneficial effects of freely administered celastrol as low dosage (2.66 µM) increases 
the Hsp70 expression, however higher dosages (5.33 µM) seems to activate the 
negative feedback loop and the beneficial effect is diminishing (Figure 23c). The 
A549 cells that are derived from lung tissue shows different activation kinetics, 
requiring higher concentrations (around 3.55 µM) for proper activation of the heat 
shock response (Figure 23d). When comparing the freely administered drug results 
with the results obtained by drug-loaded MSNs, there is a clear trend where the 
nanocarrier system prolongs the beneficial effect without the negative feedback loop 
being turned on. This prolonged efficacy is probably do the steady release kinetics of 
celastrol from these functionalized nanoparticles (Figure 23e&f). However, the 
beneficial effect of celastrol-loaded MSNs needs to be further studied in normal 
healthy cells preferably obtained directly from patients, as immortal cancerous cells 
have an altered homeostasis and protein expression pattern that can affect the stress 
response (Elmore 2007, Lee et al. 2010a, Hongmei 2012, Gordon et al. 2014). 
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Figure 23. Active targeting increases drug efficasy. a) Flow cytometry quantification of the 
apoptotic effect of different concentrations of celastrol after 24 hours incubation with HeLa cells 
using propidium iodide (PI) staining. b) The apoptotic effect of MSNs, celastrol-loaded MSNs and 
control samples after 24 hours incubation with HeLa cells in concentrations corresponding to 5.3 
µM of free celastrol. Error bars represent ± SEM (n≥4), *** P ≤ 0.001 (adapted from I). Celastrol 
and celastrol-loaded MSNs induces the heat shock response. c) HeLa cells treated with 1.77-3.55 
μM celastrol induces the expression of Hsp70. d) A549 cells treated with 2.66-3.55 μM clearly 
induces the expression of Hsp70. e) HeLa cells treated with increasing concentration (µg/ml) of 
celastrol-loaded MSNs for 6 hours shows an induction of Hsp70 expression in concentrations over 
20 µg/ml. f) A549 cells treated with celastrol-loaded MSNs increases the expression of Hsp70 at 
higher dosages 40-60 µg/ml (adapted from II). 
 
5.11. Image quantification verifies targeted drug delivery 
We utilized image quantification in order to verify successful targeted drug delivery 
as an end point measurement (II). Advanced bioimaging and image analysis has 
grown to become one of the key methodologies in biomedical research today, where 
it is possible to acquire both qualitative and quantitative data from the same data set 
(Nat Methods 2012). However, developing tailor-made image analysis workflows for 
specific purposes is required in order to transform the vast arrays of image data 
produced into meaningful quantitative information (Hartig 2013, Eliceiri et al. 2012). 
In this part of the study, we developed an automated imaging workflow based on 
BioImageXD an open source software package that were utilized to detect targeted 
cellular responses at the single cell level (Kankaanpää et al. 2012). Focusing on the 
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cellular stress response as the end point measurement; because of its vast importance 
in stress protection, stress recovery and cellular healing as proteotoxic pathologies are 
involved in neurodegenerative diseases such as Alzheimer’s and Parkinson’s (Leak et 
al. 2014, Cascão et al. 2017). As visual markers of activated stress response; nuclear 
stress bodies (nSBs) were detected by laser scanning confocal microscopy as local 
fluorescence intensity clusters of Heat shock factor 1 (HSF1) inside the cell nucleus. 
The first step in the study was to evaluate the automated workflow efficacy and 
reproducibly in identifying single cells that displayed nSBs compared to manually 
counted nSBs. For this validation we heat shocked HeLa cells at 42°C, which is 
known to induce the formation of nSBs in human cells when incubated for 15-120 
minutes, which served as an activated stress response reference for the experimental 
setup (Holmberg et al. 2000, Biamonti & Vourc'h 2010).  
The confocal images of the heat treated samples were first quantified manually by 
counting the nSBs positive cell form the total population then the same image dataset 
was then quantified using the image analysis workflow. In short, the steps for the 
automated workflow were as follows; 1) the cell nucleus was detected from the DAPI 
channel where the amount of cells can be calculated then 2) the nSBs were measured 
with dynamic thresholding and 3) object separation from the HSF1 channel. By 4) 
object-based co-localization it was possible to calculate the percentages of nSBs 
positive cells from the total population that had one or more stress granule(s) in the 
nucleus (II). The results from the heat shocked HeLa cells show that both methods 
give similar mean values, as there is no statistical difference between the two 
quantifications, demonstrating the potential of the automated image analysis (Figure 
24). Both quantifications show that there is a temperature and time dependent 
formation kinetics of nSBs in HeLa cells correlating with previous studies, validating 
the usefulness of the image quantification workflow in detecting nSBs formation 
under different conditions (Figure 24; Holmberg et al. 2000). Furthermore, utilizing 
imaging workflows it is possible to obtain information regarding size distribution of 
object of interest, in this case the size distribution of nSBs from 3D image dataset, 
which would manually be too laborious and subjective in order to execute precisely 
(Figure 24c; Nat Methods 2012, Kankaanpää et al. 2012, Carpenter et al. 2012).  
Celastrol has the ability to induce the heat shock response that increases the expression 
of heat shock proteins, however celastrols effect on the formation of nSBs have 
remained rather elusive (Salminen et al. 2010, Westerheide et al. 2004). In this part 
of the study, we showed that celastrol has indeed the ability to induce the formation 
of nSBs in HeLa cells in similar manner as heat shock (II; Holmberg et al. 2000). The 
results shows that for inducing nSBs by celastrol in HeLa cells the concentration needs 
to be over 3.55 µM and that the optimal dosage is around 5.33 µM as higher dosages 
reduces the amount of nSBs positive cells in the population probably due to negative 
feedback loop or induced toxicity (II; Nagase et al. 2003). Most importantly there is 
no significant difference in the quantification methods validating the usefulness of our 
tailor made image quantification workflow for numerous biological research 
scenarios. Furthermore, the innate batch processing capability would even enable high 
throughput imaging applications to be combined with both 2D and 3D image data 
analysis are useful traits for future personalized diagnostics. Taken together, the 
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results shows that these celastrol-loaded MSNs could potentially be beneficial for 
patients with protein aggregate associated diseases by inducing a specific and 
effective heat shock response in the target cells. 
 
 
 
Figure 24. Formation kinetics of nSBs in heat shocked HeLa cells. a) The confocal images 
shows that cells that have been heat treated for 15 minutes at 42°C only have a few HSF1 
accumulations in the nucleus, whereas 30 and 120 minutes of heat shock induces clear formation 
of nSBs in almost all cells. Control cells that have been cultured in 37°C does not form nSBs, scale 
bar 15 µm. b) Both quantification methods show similar heat shock induced nSBs kinetics, as there 
is no significant (ns) difference between the manual and computer based methods. Manually 
counted cell number (n=338), computer based analyzed cell number (n=357), error bars represent 
± SEM. c) Size distribution in µM of nSBs in HeLa cells after 120 minutes of 42°C heat shock, 
quantified from 3D datasets (n=332; II). 
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Figure 25. Celastrol-loaded MSNs induce targeted nSBs formation in FR-positive cells. a) 
HeLa cells treated with celastrol-loaded MSNs shows clear induction of nSBs when administered 
over 40 µg/ml of drug-loaded MSNs. b) A549 treated cells shows no nSBs formation even the 
highest dose of 60 µg/ml celastrol-loaded MSNs, scale bar 15 µm. c) Manually counted nSBs 
positive cells shows that there is a significant difference between cell lines when treating with 40 
and 60 µg/ml of drug-loaded MSN. d) Computer based quantification shows similar results where 
HeLa cells show a significant increase in the percentage of stressed cells compared to A549 cells 
treated with same concentration. Both quantifications methods show that concentration lower than 
40 µg/ml does not induce formation of nSBs in HeLa or A549 cells. Number of cells analyzed in 
the manually counted quantification (n=2368), and with the computer based quantification 
(n=2436), error bars represent ± SEM, **** P ≤ 0.0001 (II). 
 
One of the major benefits of targeted drug delivery is the higher drug accumulation at 
target tissue compared to the off-target tissues, which is important in administering 
molecules that gives beneficial effects in low dosage but toxic effect in higher dosages 
(Salminen et al. 2010, Jo et al. 2010, Muller & Milton 2012). Therefore, we loaded 
celastrol in FA conjugated MSNs in order to evaluate if these particles could be 
potential candidates in personalized medicine where activated heat shock response 
could be beneficial in FR expressing target tissues. HeLa cells were selected as the 
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FR positive cell line and A549 cells were selected as the FR negative cell line in order 
to validate the potential targeted effect and unwanted off-target effect. The results 
shows that when comparing the percentage of nSBs positive cells after 6 hours 
treatment of celastrol-loaded nanoparticles in both cell lines, a significant induction 
of nSBs formation in HeLa cells can be detected, whereas no formation of nSBs can 
be detected in A549 cells (Figure 25). Already at 40 µg/ml of celastrol-loaded 
nanoparticles (around 3.55 µM celastrol); both the manual and computer based 
quantifications gives about 20% nSBs positive population of HeLa cells however this 
concentration give no effect reagarding nSBs formation in A549 cells (Figure 25). 
When HeLa cells were treated with 60 µg/ml of celastrol-loaded MSNs (~5.33 µM 
celastrol) there was over 60% of the population showing formation of nSBs in the 
nucleus whereas the A549 cells did not show any detectable nSBs (Figure 25c&d). 
The significant differences between HeLa and A549 cell lines in terms of nSBs 
positive cells validates that celastrol-loaded and FA conjugated nanoparticles can be 
used as effective targeted therapies towards cells that express FR at their cell 
membrane for fighting diseases caused by protein aggregation.  
5.12. Multidrug-loaded MSNs increases efficacy  
Metastatic tumors are the main cause of cancer-related death, as the invasion of 
cancerous cells towards healthy tissues disrupts organ function that can be fatal for 
the patient (Riihimäki et al. 2013, Anderson et al. 2018). Therefore, it is important to 
create new forms of cancer treatment that are more efficient with fewer side effects 
on the patient. This is especially true when the cancer has created metastases and 
multiple surgery is too dangerous for the patient for being a plausible treatment option 
(Miller et al. 2013, Tohme et al. 2017). By giving combination chemotherapy it is 
possible to combat metastatic cancers where one drug blocks the invasiveness of the 
cancer and another induces apoptosis, however such drug cocktails often has severe 
adverse effects on the patient (Preissner et al. 2012). Therefore, by loading a carrier 
systems with combination therapy it would be possible for targeted drug delivery 
towards cancer cells with synergistic effect with significantly less side effects 
compared to the freely administered drugs (Rosenholm et al. 2009, Hu et al. 2017). 
In this part of the study, we created a multidrug-loaded nanoparticle that specifically 
targets cancer and releases synergistically two different drugs with two different 
mechanism of action for increasing drug efficacy and minimizing possible negative 
effects (III). The MSNs were loaded with an anti-proliferating molecule fingolimod 
(FTY720) that works by inhibiting the phosphorylation of sphingosine and thereby 
blocks the production of the bioactive molecule sphingosine 1-phosphate (S1P), 
which is an important signaling lipid for cell growth, survival and migration. By 
blocking the production of S1P by targeted drug delivery, these metastatic cancer cells 
are immobilized and pushed towards apoptosis (Loveridge et al. 2010). As the active 
ligand, we selected methotrexate (MTX) which is a folate antagonist that has been 
used for chemotherapy for decades (Huennekens 1994). MTX therapeutic efficacy 
works by mimicking folate that is essential in the synthesis of thymine and purine 
nucleotides thereby leading to cell cycle arrest and ultimately cell death in 
proliferating tumors (Goodsell 1999).  
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Figure 26. Flow cytometry quantification of the cellular uptake of different functionalized 
MSN in cancerous thyroid cells and normal thyroid cells after 4 hours incubation. a) % FITC 
positive ML-1 cells using 1.5 - 5 µg/ml of nanoparticles, showing high internalization of these three 
different MSNs. b) % FITC positive Nthy-ori 3-1 cells administered 1.5 - 5 µg/ml of nanoparticles 
gives lower internalization kinetics that the cancerous counterpart. Error bars represent ± SEM 
(n=3), * P ≤ 0.05, ** P ≤ 0.01 (III). 
 
First, the two MTX conjugated MSNs versus PEI functionalized MSNs uptake 
efficacy was measured using flow cytometry (III). The cell lines utilized were FR 
expressing cancerous thyroid cells (ML-1) as well as normal thyroid cells (Nthy-ori 
3-1) that express lower amounts of FR. The results shows that after 4 hours 
incubations the MSN-PEI-MTXaq are internalized in higher efficacy in both cell lines, 
and was therefore selected as the functionalized particle for further study (Figure 26). 
Intriguingly the uptake efficacy of MTX conjugated MSNs in the ML-1 cells were 
significantly lower than the uptake of FA functionalized MSNs using the same 
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concentration, time point and cell line (Figure 20&26). This difference could possibly 
be explained by that the drug MTX already starts affecting the cell homeostasis 
slowing down receptor turnover, or possibly because MTX having lower affinity for 
the FR than FA and would therefore be less efficiently internalized by FR expressing 
cells (III; Wong & Choi 2015).  
 
 
Figure 27. Viability measurement using WST-1 metabolic assay for detecting combination 
drug efficacy in cancerous thyroid cells and normal thyroid cells after 72 hours incubation. a) 
The metabolic assay shows similar decreasing viability when increasing drug concentration in the 
ML-1 cells in using both the free drug combination and the drug-loaded MSNs. b) The Nthy-ori 3-
1 cells are sensitive to the free drug cocktail whereas the drug-loaded MSN shows significantly less 
off-target effects. Values normalized to control (untreated sample) next to 0.2% v/v DMSO (vehicle 
control). Error bars represent ± SEM (n=3), * P ≤ 0.05, ** P ≤ 0.01, **** P ≤ 0.0001 (III). 
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 Then, the selected carrier system (MSN-PEI-MTXaq) was loaded with FT720 in order 
to estimate the enhanced effect of multidrug-loaded nanoparticles compared to free 
drug. The concentrations used in both the free drug and the calculated amounts of 
drugs in the MSNs were as follows: 0.065 µM MTX and 1.22 µM FTY720, 0.13 µM 
MTX and 2.43 µM FTY720, 0.219 µM MTX and 4.05 µM FTY720, 0.349 µM MTX 
and 6.48 µM FTY720, 0.438 µM MTX and 8.10 µM FTY720. As the drug 
combination induces necrosis and cell blebbing resulting in cell fragments that are 
hard to analyze in flow cytometry and confocal microcopy we utilized a metabolic 
assay for detecting the cell viability of the drug combination treatment (III). The 
results shows similar efficacy in terms of decreasing metabolic activity in the ML-1 
cells when administering similar amount of either free drug combination or drug-
loaded MSNs (Figure 27a). More importantly, the results shows that there is 
significantly less off-target effects in the normal thyroid cells when administering the 
drug-loaded MSNs compared to the free drug cocktail (Figure 27b). Based on the 
WST-1 measurements the in vitro peak anti-cancerous efficacy in the ML-1 cells 
without toxicity in the Nthy-ori 3-1 cells would be around 4.05 µM FTY720 and 0.219 
µM MTX, and that concentration was selected for further validating the apoptotic 
efficacy of the drug combination (Figure 27).  
 
Figure 28. Traditional in vitro viability measurements of combination drug efficasy. a) Cell 
viability in ML-1 cells using crystal violet after 72 hours incubation of free drug cocktail or drug-
loaded MSN normalized to control samples shows increased efficacy in terms of anti-cancerous 
activity in the drug-loaded particles (n=4). b) Cell viability of Nthy-ori 3-1 cells by cell counting 
after 72 hours of incubation of cells with either free FTY720 and MTX or multi drug-loaded MSNs 
normalized to control samples (n=3). Drug concentration used: 0.219 µM MTX and 4.05 µM 
FTY720. Error bars represent ± SEM, ***, P ≤ 0.001 (supp. file III). 
 
Because of the limited toxicity measurements available for highly fragmenting cells 
as a result of the drug treatment, we utilized a more traditional approach by cell 
counting and crystal violet for validating the drug efficacy (Figure 28; Kroemer et al. 
2009). The cell viability by cell counting shows a significant difference in the toxic 
effect after 72 hours detected in the normal thyroid cells when administering the free 
drug cocktail compared to the drug-loaded MSN in similar concentration of drugs 
(Figure 28b). Validating that these multidrug carrier systems have significant less off-
target effects in normal thyroid cells that express low amounts of FR even though 
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small amounts FA conjugated nanoparticles are internalized in these cells (Figure 
20&28). In addition, the drug-loaded MSN showed higher anti-cancerous efficacy in 
ML-1 cells when using crystal violet as viability assay (Figure 28a). However, shorter 
time points than 72 hours did not induce apoptosis when administering drug-loaded 
MSNs which is most likely due to the release kinetics of the anti-cancerous drug MTX 
being conjugated at the surface of the particle as enzyme driven drug release in target 
cells takes more time (Popat et al. 2012). 
In order to validate the results obtained from the traditional viability assays we utilized 
image analysis performed by external experts using the instrument Phasefocus VL21 
that utilizes light for reconstructing an image of the samples refractive properties 
without labeling and toxic lasers (III; Marrison et al. 2013). The reconstructed images 
shows that ML-1 cells administered either the free drug cocktail or the drug-loaded 
MSNs both showed a more rounded up phenotype compared to the elongated spread 
out normal phenotype of the control sample (Figure 29a). The results from the image 
quantification done by the external experts are as follows: “The volume of the drug 
treated cells also begins to decrease, resulting in a significant reduction compared to 
control cells by day 4 of treatment. Indeed, blebbing, which is evident in VL21 images 
of both drug-treated groups from day 3 onwards, is often accompanied (and followed 
by) a reduction in cell volume as cells die”. The statistical analysis verifies that both 
free drug and drug-loaded MSNs decreases cell volume after 72 hours compared to 
control, and that sphericity was decreased in the drug-loaded MSNs compared to the 
free drug treatment (Figure 29b&c). This quantification detecting the decrease in 
sphericity combined with the VL21 images showing blebbing of cells is an indication 
that these ML-1 cells exhibit a more apoptotic/necrotic phenotype after administration 
of nanoparticle loaded with FTY720 and MTX compared to freely administered drug 
cocktail. Furthermore, the experts concluding statements are as follows: “The silica 
nanoparticles potentially enable drug retention during transit to the target cancerous 
site, preventing off-target killing of non-cancerous tissues, but enable release of the 
drug in order to effectively kill cells at the target destination”.  
Taking together, our proposed multidrug-loaded MSN could potentially be considered 
to combat metastatic tumors originated from thyroid cells when the drug efficacy and 
potential off-target effects are further studied in vivo (see next section). As the drug 
cocktail induced cell death leading towards cell fragmentation there was limited in 
vitro cell viability methods available. Many cancer drugs have high lipophilicity and 
low water-solubility, which is also true with the selected drugs that makes it hard to 
administer the drugs to target cells due to limited bio-distribution. In this study, the 
poorly water soluble drug methotrexate was conjugated at the surface of the particle 
that increased it bio-distribution as the PEI branching with its positive charge makes 
the nanoparticle more dispersible in aqueous solution. The second drug fingolimod 
(FTY720) was loaded inside the pores shielded by the PEI branching functioning as a 
molecular gate preventing premature release. This means of drug encapsulation and 
drug conjugation explains the slow release of the drugs from the nanoparticle as 72 
hours of incubation time was necessary in order to achieve an effective response in 
target cells compared to the freely administered drug cocktail that gave a faster non-
specific response in both cell lines.  
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Figure 29. Phasefocus measurments of ML-1 cancer cells treated with MTX and FTY720 or 
MSN loaded with drug combination. a) The multidrug-loaded MSN treated cells are more 
necrotic and apoptotic than the cells treated with the free drug cocktail, seen as more condensed 
cells in the MSN treated, scale bar 150 µm. Image quantification showing the b) volume and c) 
sphericity of the cell populations in control, free drug and drug-loaded MSN. The image analysis 
shows that the ML-1 cells administered with drug-loaded MSNs have after 4 days a less spherical 
phenotype and smaller volume compared to cells treated with free drugs. Statistics in black indicate 
comparison between control and drug-treated samples. Points of statistical significance between 
control and treated samples or difference between free drug samples and drug-loaded MSNs 
indicated by red asterisks. Drug concentration used: 0.219 µM MTX and 4.05 µM FTY720. Number 
of cells analyzed (n=1524). Error bars represent ± SEM, **, P ≤ 0.01, ***, P ≤ 0.001 (III). 
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Furthermore, it is possible that the free drug efficacy was at least partly due to the fact 
that drug FTY720 is not water insoluble and therefore, partial drug dissolution in the 
cell medium occurred that induced cell death in the administered cells (data not 
shown). This drug dissolution could at least partly explain the in vitro results that 
clearly demonstrate that the free drug cocktail has significantly more off-target effect 
on the normal thyroid cells than the multidrug-loaded MSNs (Figure 27). Another 
plausible explanation could be that the normal thyroid cells are more sensitive to 
foreign materials than their cancerous counterparts (Figure 21). These findings 
regarding efficacy differences were further validated by propidium iodide staining and 
by the Phasefocus image analysis showing significantly more apoptotic cells 
quantified as rounding up and blebbing of thyroid cancer cells given the drug-loaded 
MSNs compared to freely administered drug cocktail (III). 
5.13. In vivo efficacy studies of multidrug-loaded MSNs 
After successful in vitro studies showing nanoparticle accumulation, retention and 
specific drug release in target cells; the selected carrier systems were further tested in 
vivo in order to confirm their efficacy in a more clinically relevant setting. In order to 
keep the cost at a reasonable level the chick chorioallantoic membrane (CAM) assay 
was utilized for the in vivo studies (Zeisser-Labouèbe et al. 2004). The CAM is a 
highly vascularized extraembryonic membrane that is important during embryonic 
development functioning as a barrier and gas exchange system. The CAM assay has 
received increased interest in the field of cancer research and drug development during 
the last decades, as the tumors are easily accessible for experimental manipulation 
(Nowak-Sliwinska et al. 2014). Furthermore, the chick embryo is naturally 
immunodeficient, supporting the inoculation of both normal and cancerous human 
cells (Zijlstra et al. 2002). Therefore, the avian CAM makes an exceptionally useful 
model in investigating cancer cell behavior such as tumor growth, invasion, 
angiogenesis and the remodeling of the surrounding tissue (Zijlstra et al. 2002, 
Zeisser-Labouèbe et al. 2004, Kain et al. 2013).  
The drug efficacy in terms of inhibition of invasiveness of cancer cells was studied on 
ML-1 derived xenografts by measuring the tumor weight and tumor size by image 
quantification combined with histology for classifying tumor phenotypes (Ossowski 
& Reich 1980, Nowak-Sliwinska et al. 2014, Lokman et al. 2012). In short, the image 
quantification were done using ImageJ by manually selecting the tumor area of first 
the pre-treated tumors then comparing that area with the post-treated tumor area of 
the same tumors giving the difference in tumor size in percentages (Kalhori et al. 
2016). The drug cocktails were suspended in HEPES buffer before topical 
administration and the concentration of both free drugs and MSN loaded with drugs 
was 1 µg MTX and 13 µg FTY720 per used egg. The control tumors (0.5% DMSO 
and 1.6 mg/ml empty MSN) showed significant reduction in size from pre-treatment 
on EDD 9 to post-treatment on EDD 12 demonstrating that these ML-1 cells are highly 
invasive (Figure 30&31). The selected multidrug-loaded carriers systems showed 
significant retention of the tumor mass on the CAM compared to the freely 
administered drug combination (Figure 31c). This increased retention effect by drug-
loaded MSNs was validated by image analysis quantifying the tumor size combined 
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with weighing the removed tumor masses after the treatment (Figure 31b&c). The 
result indicates that these multidrug-loaded MSN has the ability of blocking the 
invasiveness of these ML-1 derived xenografts (Figure 31). Furthermore, the 
histology shows that these drug-loaded MSN inhibit the epithelial-mesenchymal 
transition (EMT) seen as a decrease of EMT marker vimentin as well as a decrease in 
thyroid transcription factor 1 (TTF-1) which is considered a metastatic marker by 
pathologists (Figure 32; Sotiriou et al. 2017). The hematoxylin and eosin (H&E) 
staining of whole tumors validates the highly metastatic nature of the ML-1 cells in 
the both control tumors seen as invading tumor cells at the chick chorioallantoic 
membrane whereas both drug treated tumors has a non-invasive phenotype (Figure 
30). The histology also shows that the tumors treated with the drug-loaded MSNs has 
an more necrotic/apoptotic phenotype seen as nuclear condensation and cell fragments 
compared to the other tumor samples (Figure 30&32). 
 
 
Figure 30. Hematoxylin and eosin (H&E) histological staining of ML-1 xenografts grown on 
chorioallantoic membrane (CAM). a) Control (0.5% DMSO) tumor showing invasion of the ML-
1 cells through the CAM indicated by black arrow. b) Particle control (1.6 mg/ml empty MSN) 
tumor showing clear invasion of cancer cells to CAM epithelial cell layer indicated by black arrow. 
c) The free drug treated tumors shows non-invasive behavior of the cancer cells. d) The drug-loaded 
MSN treatments shows necrotic and apoptotic morphologies indicated by black arrow as well as 
loss of invasive phenotype. Scale bar 500 µm. (supp. file III). 
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Figure 31. Chick chorioallantoic membrane (CAM) assay for evaluating the in vivo drug 
efficacy. a) Images of pre-treated and post-treated tumors showing decreased tumor size in control 
(0.5% DMSO), particle control (1.6 mg/ml empty MSN) and free drug treatment (1 µg MTX and 
13 µg FTY720). The drug-loaded MSNs (1 µg MTX and 13 µg FTY720) treatment shows clear 
retention in post-treatment tumor size as well as yellow and white discolorations as signs of 
inflammation and necrosis. b) Image quantification of mean visible tumor size of post-treated 
tumors normalized to pre-treated tumors size shows decreased tumor size on all samples except the 
drug-loaded MSN showing a retention of tumor size c) Post tumor weighing shows significantly 
larger tumors after the drug-loaded MSN treatment validating the anti-invasive efficacy. Error bars 
represent ± SEM (n≥4), **** P ≤ 0.0001 (III). 
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In addition, the necrotic phenotype of the ML-1 xenografts can visually be detected 
as disrupted morphology and discoloration of the tumor mass seen on the images 
(Figure 31a; Grey et al. 2006). However, the invasiveness of these cancer cells as well 
as the potential inhibition by drug-loaded MSNs needs to be further studied, 
preferably by detecting the human genetic content in different organs as a marker of 
metastasis or histology of the chicken embryo organs using human antibodies for 
detecting the possible tumor cells (Sotiriou et al. 2017, Maacha et al. 2018). 
Unfortunately, such detailed in vivo experiments regarding the invasiveness of these 
tumors were not plausible at that time due to limited resources. Therefore, in the next 
part of the study, we utilized in vitro invasion assay for validating the metastatic 
potential of these ML-1 cells as well as the inhibitory effect of the combined drug 
cocktail. Taken together, our nanoparticle containing two active molecules has an 
advantage in terms of anti-cancerous activity than nanoparticles with only one active 
agent for inhibition of metastasis and inducing cell death in thyroid cancer cells. 
Figure 32. Immunohistochemistry staining of ML-1 xenografts grown on CAM. The H&E 
staining shows migrating cells in control and empty particle samples whereas the drug treated cells 
do not display invasive phenotype. High vimentin expression in all samples except the drug-loaded 
MSN treated samples indication of the drug inhibiting the EMT. The ML-1 xenografts exhibits a 
low proliferative profile shown as weak Ki-67 staining and some variable basal caspase-3 activity 
in all samples seen mostly in the center of the tumor. Clear decrease of TTF-1 staining in drug-
loaded MSNs treated tumors compared to all other samples indicating a less malignant phenotype. 
Scale bar 50 µm (adapted from III). 
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5.14. Invasion assay validates inhibitory effect of the drug cocktail 
In order to validate that the drug cocktail inhibits the metastasis of these thyroid cancer 
cells; invasion assay were utilized using 8 µm pore size inserts with collagen IV 
coating for mimicking physiological relevant conditions of the extra cellular matrix 
(ECM; Kramer et al. 2013, Justus et al. 2014). High concentration (20%) of fecal 
bovine serum (FBS) was used in the lower well as the chemoattractant in order to steer 
the direction of the cells through the inserts. The ML-1 cells exhibited rapid 
invasiveness as the optimal time point for counting the migrated cells were at 7 hours 
and not 24 hours that is often used for low motility cells (Kramer et al. 2013, Justus 
et al. 2014). The drug concentrations of MTX and FTY720 were as followed; the low 
dosage was 0.13 µM MTX and 2.43 µM FTY720 the high dosage was 0.438 µM MTX 
and 8.10 µM FTY720. The result shows that the high drug dosage inhibits efficiently 
the migration of the ML-1 cells seen in the microcopy images from the invasion assay 
(Figure 33). The quantification obtained from the invasion assay validates that the 
drug combination treatment does in fact block the invasiveness of these ML-1 cells 
demonstrating the potential of this combination therapy (Figure 33d).  
Intriguingly, the lower dosage significantly increases the cancer cell invasion 
functioning as an accelerant. This was seen as an increased migration of the ML-1 
cells from the upper well towards the lower well when comparing to the untreated 
condition (Figure 33). However, such opposite effect of the low concentration drug 
cocktail would need further study in order to validate the underlying mechanism seen 
in this study. Nevertheless, several other studies have shown that a drug can exhibit a 
biphasic effect, where the low dosage has a stimulating effect, and the high dose has 
an inhibitory effect (Bhakta-Guha & Efferth 2015). Furthermore, the same experiment 
setup was conducted using drug-loaded MSNs instead of freely administered drug 
(data not shown). The result obtained using the drug-loaded MSNs showed non-
significant effect on the invasion of these ML-1 cells, which corresponds to the results 
from the viability experiments showing that over 24 hours is necessary for the drug to 
be released in target cells in order to induce an effect. Therefore, an 7 hours 
experiment where the freely administered compound can immediately give an anti-
invasive effect comparing those results with another treatment form where 7 hours is 
not even enough for the carrier system to release the drug compound is like 
“comparing apples and oranges”. By prolonging the incubation time to 24 hours it 
could, in principle, be possible to compare the results of the two treatment forms. 
However, the toxic effect of the freely administered drug would be the governing force 
seen in the 24 hours viability assay (data not shown), and the “side effect” of the dying 
ML-1 cells would most likely be lower invasion score and not the actual anti-invasive 
effect. Taking together, the invasion assay verifies that the MTX and FTY720 drug 
combination does indeed inhibit the invasiveness of thyroid cancer cells. However, 
further more clinically relevant in vivo studies needs to be executed for validating the 
anti-invasive potential of these multidrug-loaded MSNs in order to go towards product 
development.  
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Figure 33. Invasion assay showing crystal violet-stained ML-1 cells after 7 hours. a) In the 
control sample ML-1 cells are visible on the insert after 7 hours showing that the cells are highly 
invasive. b) Low dosage of combination treatment (0.13 µM MTX and 2.43 µM FTY720) shows 
slight increase in the invasive potential of the ML-1 cells compared to control. c) The high dosage 
(0.438 µM MTX and 8.10 µM FTY720) show less migrating ML-1 cells on the insert and the d) 
quantification of the invasion assay validates that the high combination treatment block the 
invasiveness of these ML-1 cells. Error bars represent ± SEM (n=4), ** P ≤ 0.01, *** P ≤ 0.001 
(III). 
 
5.15. Validating the hypothesis of MSNs for targeted drug delivery 
In order to validate an academic idea, concept or mechanism; one have to find the 
appropriate methods for testing the null hypothesis which is an default position where 
there is no relationship between two measured phenomena or no association among 
the different groups (Banerjee et al. 2009, Pernet 2016). In targeted drug development, 
that null hypothesis could be that “there is no enhanced targeted drug efficacy when 
utilizing the carrier system compared to freely administered drug”. Subsequently 
using different relevant methods for testing if the drug carrier has an increased effect 
on target cells and lower effect on off-target cells. If the data shows a statistically 
significant difference between the two groups the null hypothesis is rejected and an 
alternative hypothesis can be accepted in its place. In these academic studies, the 
alternative hypothesis was that the carrier system functions as an effective targeting 
strategy that could be employed in the future for minimizing human suffering (I-III).  
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However, when conducting experimental setups with carrier systems versus freely 
administered drug compounds it is not always an easy and straightforward task as the 
release mechanism and as a consequence the drug effect of the two administrations 
can be quite different. Therefore, during the idea phase of the development of targeted 
drug delivery, it is important to consider the targeting strategy in order to achieve 
maximal uptake in target cells with minimal off-target internalization together with 
selecting the relevant methods for testing the null hypothesis. Then the drug of interest 
need to be carefully considered for appropriate loading so that the drug matches the 
properties of the carrier system, for example, a water-soluble drug loaded inside the 
porous structure of an MSN would result in a premature release of the drug in the 
extracellular space giving potential off-target effect (Desai et al. 2014). Or making a 
particle with pore size of a few nm for drug adsorption and then load the particle with 
large hydrocarbon molecules that are too big for the porous structures and, as a 
consequence, the drug would be attached on the surface of the particle creating a 
leaking particle system instead of targeted drug delivery. The saying that “everything 
affects everything” holds some truth in the development of nanoparticles for targeted 
drug delivery; and therefore, a case-by-case evaluation on these man-made materials 
would be preferred as generalizations will often give a misleading interpretation of 
both the efficacy and toxicity of nanomaterial based carrier systems (Paaby & 
Rockman 2012, Desai et al. 2014, Pillai 2014, Bobo et al. 2016, Bremer-Hoffmann et 
al. 2018). 
Therefore, in this thesis, these MSNs were scrutinized by diverse scientific methods 
and by pushing the experimental setup by using high concentrations of particles, 
longer incubation times and utilizing different cell lines that made it possible to obtain 
relivable data showing that the alternative hypothesis holds true that these carrier 
systems could be used for targeted drug delivery for specific cell types in certain 
disease conditions originated from disruption in the cellular homeostasis (I-III). The 
null hypothesis was rejected in the first study, as the drug efficacy in terms of 
apoptosis showed significant (p-value less than 0.001) enhancement when utilizing 
celastrol-loaded sugar decorated MSNs compared to free drug in cervical cancer cells 
(Figure 23). In the second study, the null hypothesis was rejected as the efficacy in 
terms of inducing the stress response using folic acid functionalized celastrol-loaded 
MSNs showed superior efficacy compared to freely administered drug as the p-value 
was under 0.0001 (Figure 25). In the third and last study the null hypothesis was 
rejected as the multidrug-loaded MSNs showed significant (p-value less than 0.0001) 
retention of tumor size compared to the freely administered drug cocktail combined 
with significant efficacy (p-value less than 0.001) in terms of cell viability when using 
MTX and FTY720 loaded nanoparticles (Figure 31&28). However, as empirical 
science cannot be ‘proven’ by statistical significances the alternative hypothesis was 
selected as the most plausible explanation based on the results as a whole (Banerjee 
et al. 2009, Robergs 2017, Amrhein et al. 2019). 
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6. CONCLUSION AND FUTURE PROSPECTS 
Cancer is one of the main causes of death in the western world and the numbers are 
estimated to rise; by the year 2020 there will be over 15 million new cancer cases 
worldwide. Traditional chemotherapy that arise after the first and second world war 
with all their potential side effects started the race towards targeted drug development, 
and the first breast cancer drug, tamoxifen, came out on the market in the 1970s. The 
advancement in the past decades in the knowledge of oncogenes and tumor suppressor 
genes together with digitalization and the development of sophisticated instruments 
has paved the way for personalized medicine. Nanomedicine is an emerging 
interdisciplinary field that combines nanotechnology with medicine for the 
development of therapeutics that could be used for personalized drug delivery and 
diagnostics for increased accumulation and retention of drug molecules in target tissue 
while minimizing potential off-target effects. Nanoparticles have shown great 
potential as drug delivery vehicles due to low toxicity, high drug loading capacity 
together with tailor-made surface functionalization for cell specific internalization, 
thus increasing the therapeutic index and lowering the possible side-effects of the 
drug. Inorganic silica based nanoparticles were selected as the drug carrier system, as 
they can be loaded with hydrophobic molecules and allow ease of functionalization 
of different targeting motifs combined with being biocompatible and biodegrade, as 
silica degrades in aqueous environment to silicic acid and ultimately gets excreted via 
urine. In this thesis, different targeting strategies utilizing mesoporous silica 
nanoparticles (MSNs) were developed and studied for estimating the targeted delivery 
and the potentially increased drug efficacy and possible off-target effects of these 
carrier systems.  
In the first part of the study, we investigated the potential use of glucose conjugated 
MSNs to selectively and efficiently deliver the hydrophobic drug celastrol to sugar 
craving cancer cells. We evaluated internalization of sugar-derivatized MSNs via 
eight different surface functionalization regimes by flow cytometry, confocal 
microscopy, spectrophotometry and image analysis, from which the functionalization 
that had the highest uptake in cancer cells while keeping the uptake in healthy cells 
reasonably low, was selected for further drug efficacy studies. The particle design 
with a hyperbranched, PEI polymeric surface structure together with the selected 
(GAorg) sugar moiety providing an overall net positive surface was then loaded with 
small amounts of celastrol for evaluating the potentially gained anti-cancerous 
efficacy. The results show that there was no premature drug release of the selected 
carrier system under physiological conditions, thereby minimizing possible off-target 
effects that might give rise by freely administered celastrol. The glucose conjugated 
particle uptake in target cancerous cells was around five times higher than in the 
normal cells. Furthermore, the drug efficacy in terms of inducing apoptosis in cancer 
cells were remarkably enhanced when using the GAorg functionalized MSN compared 
to the same amount of free celastrol. Taken together, our results shows that sugar-
decorated MSNs loaded with the poorly water soluble drug celastrol has the ability to 
efficiently enhance and induce apoptosis in cancer cells with minimal uptake in off-
target healthy cells. 
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In the second study, we investigated the use of a tailor-made BioImageXD-based 
quantification method for counting and analyzing nuclear stress bodies (nSBs) in 
folate receptor (FR) positive cells induced by folic acid (FA) functionalized celastrol-
loaded nanoparticles. The computerized quantification method was first validated by 
comparing the nSBs formation kinetics induced by heat shock with manually counting 
the nSBs positive cells from the whole population. The quantifications showed that 
there was no significant difference between the two methods; demonstrating that the 
automated image analysis workflow can be accurate, reliable and versatile for 
detecting and quantifying nSBs in stressed human cells. The image based 
quantification validates the specific drug delivery capabilities of these celastrol-
loaded MSNs, as demonstrated by highly significant differences between the nSBs 
activation kinetics when comparing the FR-positive HeLa population with the FR-
negative A549 population. Furthermore, the heat shock response was studied by 
western blot, indicating that the celastrol-loaded MSNs increased the expression of 
the molecular chaperone Hsp70 in HeLa cells already at low dosages, and that those 
similar concentrations did not properly induce the stress response in A549 cells. Taken 
together, the results of this study show that celastrol-loaded MSNs could potentially 
be beneficial for patients with protein aggregate associated diseases by inducing a 
specific and effective heat shock response in the target cells. Combining the targeted 
drug delivery capabilities of these MSNs with our computerized image quantification 
methods for detecting and characterizing nSBs positive cells could open up 
possibilities for future automated diagnostics and personalized medicine. 
In the third and last project, we created a multidrug-loaded nanoparticle that 
specifically targets cancer cells by utilizing an active targeting ligand methotrexate 
(MTX), which is a folate antagonist that has been used as chemotherapy for decades. 
In this manner, we created a carrier system that has a drug with targeting capability 
on the surface of the nanoparticle that opens the possibility of loading the particle with 
a second drug, in this case a Sphingosine Kinase 1 Inhibitor named fingolimod 
(FTY720). The drug FTY720 works by inhibiting the phosphorylation of sphingosine 
and thereby blocks the production of the bioactive molecule sphingosine 1-phosphate 
(S1P), which is important for cell growth, survival and migration. As a consequence 
of blocking the production of S1P by the drug FTY720; migrating cells are halted and 
pushed towards apoptosis. The active ligand MTX on the other hand blocks the 
synthesis of thymine and purine nucleotides leading to replication errors and cell death 
of the fast dividing cancer cells. The results shows that the multidrug-loaded MSNs 
has significantly lower off-target effects on healthy cells compared to freely 
administered drugs, and that the drug-loaded particles efficiently induces cell death in 
target cells. The drug cocktail induced necrosis and cell fragmentation that 
implemented some difficulty in selecting appropriate in vitro methods for evaluating 
the apoptotic efficacy. However, by using traditional cell viability assays such as cell 
counting and crystal violet it was possible to distinguish live and dead cells from the 
population showing enhanced drug efficacy in the drug-loaded MSNs compared to 
freely administered drugs. The drug efficacy was further validated by external expert 
using an advanced microscopy technique combined with image analysis showing that 
the drug-loaded MSNs induced enhanced apoptosis in target thyroid cancer cells 
compared to freely administered drug cocktail detected as increased blebbing, 
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fragmentation and rounding up of dying cancer cells. Furthermore, the drug cocktail 
efficiently blocked the thyroid cancer cells migration in vitro using an invasion assay 
and the in vivo studies done on chick chorioallantoic membrane (CAM) assay showed 
that the drug-loaded MSNs retained the tumor size thus blocking the cancer cell 
invasion towards the chicken embryo. The histology done on the in vivo tumors shows 
that the drug-loaded MSNs also blocks the epithelial-mesenchymal transition (EMT) 
that is necessary for proper invasiveness of tumor cells. Taken together, our 
nanoparticle containing two active molecules has an advantage in terms of anti-
cancerous activity than nanoparticles with only one active agent for inducing selective 
and efficient apoptosis and inhibition of metastasis in cancer cells expressing folate 
receptors. 
Developing targeted drug delivery is not a simple task, going from idea towards 
reality, where material composition and functionalization needs to be carefully 
considered for successful drug loading and maximizing targeted drug delivery for 
each specific cell type. The drug carrier itself needs to be biodegradable and non-toxic 
in the administered dosages in order to minimize possible side effects in patients. 
However, in order to advance to clinical trials, massive in vitro and in vivo studies 
need to be executed and passed with excellence. Combined with the monetary 
challenges of today’s research with the potential pitfalls of protecting the intellectual 
property rights of nanomaterials, the task can be daunting. However, there are some 
Food and Drug Administration (FDA) approved nanomedicines in the market 
showing that the efforts are not futile in the pursuit of targeted medicine. For example, 
our sugar decorated celastrol-loaded MSN could be used as a first line of defense 
against cancers, as most of the human tumors have an increased metabolic rate 
compared to healthy tissues and would therefore specifically internalize our proposed 
particles in higher amounts gaining enhanced drug efficacy. Also, by integrating 
targeted drug delivery with image analysis, it would be possible in the future for 
personalized disease treatment and diagnostics that could yield in quicker 
identification of target cells, and therefore minimize possible off-target effects. 
Furthermore, by combining two different drug molecules in one drug carrier it would 
be possible to reduce the administered dosage for the patient and enhance the 
synergistic effect of the drug cocktail by specific drug uptake in target cells, yielding 
enhanced efficacy with less side effects. Taken together, the findings in this thesis 
function as an academic proof of concept demonstrating that it is possible for targeted 
drug delivery and enhanced drug efficacy utilizing functionalized mesoporous silica 
nanoparticles. However, in order to achieve the ultimate goal of creating a new form 
of cancer treatment, significant input of research and resources from both academia 
and industry would be necessary as the accumulative cost of drug development goes 
up to millions of dollars.  
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